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1 Introduction 
 
1.1 RNA interference 
 
In 1998 an article entitled “Potent and specific genetic interference by double-stranded 
RNA in Caenorhabditis elegans” was published by Andrew Fire and Craig C. Mellow.1 
In their work they discovered that the introduction of double-stranded RNA (dsRNA) 
encoding for a certain gene into cells, led to the down regulation of its gene product. 
This down regulation was more efficient for an introduced double strand then for the 
separate introduction of its single strands. For single strands it was thought, that they 
hybridize with their target messenger RNA (mRNA) leading to degradation and thus 
avoid translation (antisense strategy).2 As the effect of dsRNA was significantly higher, 
the scientists hypothesized a catalytic process. This finding, termed RNA interference 
(RNAi) was awarded with the Nobel Prize in Physiology or Medicine in 2006. 
One year after this discovery (1999) Tuschl et al. published their results on this field.3 
They had found that the dsRNA was cleaved into 21-23 nt long fragments when 
introduced into the cell. They concluded that these fragments led to gene silencing. In 
2001 Tuschl and co-workers could demonstrate that their hypothesis was right. They 
introduced synthetic, 21 nt long dsRNA, called small interfering RNA (siRNA), into 
mammalian cells resulting in a specific gene knockdown.4 These findings did not only 
revolutionize the field of cell biology and its understanding due to the opportunity to 
selectively down regulate single genes on post transcriptional level; it also opened a 
completely new, very potent platform for drug development. 
 
 
1.1.1 Molecular background of RNA interference 
 
Since its discovery the knowledge of RNA interference increased rapidly. The process 
starting with the introduction of dsRNA or synthetic siRNA into cells, resulting in a 
specific target gene silencing is understood in its details. An overview of the processes 
and structures included in the RNA mediated silencing of a gene is shown in Fig. 1.1. 
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Fig. 1.1 Mechanisms of gene silencing by introduction of dsRNA and siRNA. RISC: RNA induced 
silencing complex, mRNA: messenger RNA, siRNA: small interfering RNA, dsRNA: double-stranded 
RNA. 
 
When dsRNA enters the cell, it is recognized by an enzyme called Dicer.5 This 
enzyme cleaves the dsRNA into fragments of 21 – 23 nt also known as siRNA. 
Instead of the introduction and cleavage of dsRNA, synthetically produced siRNA can 
be introduced immediately.4 Once in the cytosol, these fragments are recognized by a 
multi-protein complex called RNA-induced silencing complex (RISC). Argonaute 2, as 
part of the RISC unwinds the siRNA. While the sense strand is released and 
degraded, the antisense strand remains incorporated in the RISC.6 If complementary 
mRNA is accessible, the complex attaches to it, resulting in cleavage of the mRNA 
followed by degradation.7-8 The RISC-antisense strand complex remains stable during 
this process and therefore is able to attach to a new corresponding mRNA 
propagating and catalyzing gene silencing. This process displays an important 
epigenetic tool for the regulation of gene expression. 
cleavage 
dsRNA siRNA (21-23nt) 
mRNA 
sense strand 
antisense strand 
cleaved mRNA 
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1.2 siRNA as pharmaceutical tool 
 
As RNAi technology results in the down regulation of a specific target gene, it is a 
potent tool for cell biological science. Moreover, since the first in vivo test using siRNA 
in 2002,9 its potential as pharmaceutical drug has been studied extensively.10-11 Many 
diseases are based on a genetic dysfunction. Besides reduction of the expression of 
an upregulated gene up to complete silencing, siRNA treatment can also lead to 
upregulation of a gene e.g. by down regulation of its suppressor proteins.12 In 
comparison to chemical drugs, siRNA has the advantage to work very specific on the 
target gene, almost without cross reactivity to any other process. Compared to other 
high specific macromolecular drugs (e.g. antibodies or peptides) it can target almost 
any cellular process based on a gene product, making former undrugable targets 
accessible. If a formulation is able to deliver the siRNA to a certain target cell, every 
mechanism can be regulated without modifying the drug characteristics (structure, 
solubility, charge, etc.). The only adoption that has to be made is the target-directed 
siRNA nucleotide sequence. Due to these advantages siRNA has been investigated 
for various diseases including inflammation, viral infections and cancer.13-18 Especially 
in case of cancer, siRNA reveals potent new therapy methods.19-20 As many genes are 
deregulated in all tumors, RNAi technology can help to reorganize the cancer cell or 
simply force apoptosis.21 
The key problem hampering a rapid development of pharmaceutical drugs is the 
problem, every macromolecule bears: the delivery process. 
 
 
1.3 Barriers in macromolecular delivery 
 
siRNA has similar limitations as many other macromolecules like proteins, peptides, 
antibodies or DNA during the delivery process.  
Depending on their function, macromolecules have to act at the surface of the target 
cell, or inside the cell. Antibodies, proteins and peptides acting e.g. as inhibitor of cell 
surface receptors or inducing a receptor based signalling cascade have just the need 
to get access to the target cell,22-23 while siRNA, antisense RNA or intracellular acting 
proteins, peptides and antibodies have to enter the cell and reach the cytosol or, 
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especially in case of DNA, enter the nucleus. While getting to the place of need, these 
molecules are faced with many problems. Local injection followed by diffusion of the 
delivered molecule to the cell of interest is one method to get huge amounts of a 
macromolecular drug to its target cell. But just a few cells or tissues can be addressed 
via this method. Direct injection in the eye has in example been used for the treatment 
of age related macula degeneration.24 Especially strong vascularized organs like liver 
or kidney, but most important metastatic tumor tissue can be addressed easier by 
systemic delivery via blood supply. According to Paul Ehrlichs philosophy of the 
“magic bullet”, the macromolecular drug should find its target cell itself after systemic 
injection, avoiding any interaction with blood compounds or non-targeted cells. In 
reality this process raises many hurdles for the drug. After injection into the blood 
stream the macromolecule is surrounded by a tremendous amount of different 
molecules, starting from serum albumin over blood cells, the immune system 
(phagocytic cells etc.) and enzymes like proteases, peptidases or nucleases. They 
interact either unspecific via ionic or hydrophobic interactions or very specific (e.g. 
enzymatic degradation). During the circulation, the macromolecule passes all different 
kinds of tissues and organs, raising new limitations. Especially clearance by liver and 
kidney is a problem during macromolecular delivery.25-26 The kidney has a size cut off 
of around 8 nm and thus allows renal clearance of small proteins peptides and 
especially siRNA with a size below this cut off. On the other hand organs with very 
small capillaries like the lung have to be passed. Thus huge delivery vehicles resulting 
from a potential aggregation have to be avoided, because they could lead to a 
hampered blood flow, followed by inefficient blood supply. 
If a delivery vehicle for the macromolecule is designed in an appropriate manner, a 
stable circulation throughout the body should be enabled. After overcoming these 
bottlenecks the macromolecule has to reach its target cell/tissue. When arrived, it has 
to leave the blood circulation and attach to the cell surface depending on its function. 
For proteins, peptides and antibodies acting from the extracellular side of the cellular 
membrane it is rather easy to address to the target cell. In general these drugs are 
designed to attach and activate or inhibit a certain antigen or cell surface receptor. 
Thus the drug is designed to recognize its target cell. In case of macromolecular drugs 
acting intracellular, the delivery process becomes more complex, because they have 
to overcome the cellular membrane. As this lipid bilayer is designed to hamper 
macromolecules from uncontrolled cell entrance, this barrier is not easy to overcome. 
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For macromolecules there are two options to pass the membrane and get inside the 
cell (Fig. 1.2 II, III). 
 
 
Fig. 1.2 Cell association and entry mechanisms for macromolecular delivery. I: Interaction of an 
extracellular acting drug with the cell surface, II: Direct transduction through the cell membrane, III: 
Internalization via a carrier system. 
 
One possibility is crossing the layer directly using cell penetrating peptides (CPP)27 or 
peptide transduction domains (PTD)28-29 (Fig. 1.2 II). These peptides are able to 
interact with the cellular membrane helping a conjugated macromolecule to attach to, 
and enter the cell. For some drugs, peptides and proteins this method works to certain 
extend, but the efficiency is strongly influenced by the physical properties (charge, 
size, hydrophobicity) of the attached macromolecule. Although it has been reported 
that the delivery of free oligonucleotides or negatively charged molecules through the 
plasma membrane is possible to certain extend,30-33 especially for negatively charged 
nucleic acids, the interaction with the negatively charged cell surface is difficult.  
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The second option of cell entrance is clathrin- or caveolae mediated endocytosis 
(Fig. 1.2 III). Endocytosis is a natural process that enables a controlled uptake of 
macromolecules. General processes initiating endocytosis are e.g. the attachment of 
special ligands to its receptors. The transferrin receptor is for example internalized 
after attachment of a Fe3+ loaded transferrin molecule.34 This process allows the 
uptake of iron-ions into the cytosol. In case of receptors that start an intracellular 
signal cascade, the receptor is internalized after ligand attachment to avoid multiple 
activation of the cascade. Besides these receptor based processes, rather unspecific 
ionic interactions can lead to the invagination of the cellular membrane resulting in 
endocytosis.35 Although the biological functions are very different, these processes 
can be used to get a macromolecule via an endosome across the cellular membrane.  
In case of direct crossing via cell penetrating peptides, the payload gets immediately 
into the cytosol, where many of the molecules (especially siRNA) are addressed to. In 
case of endocytosis, the drug enters the cell entrapped in a small compartment. As an 
endosome gets acidified and further processed to a lysosome after cell entrance, the 
macromolecular structures have to escape out of the endosome to avoid lysosomal 
degradation. After cell entrance, all modifications that have been done to the payload 
have to be cleaved off to enable the development of a fully active non modified 
structure. All these steps have to be fulfilled during delivery. If just one of these steps 
is inefficient, the efficiency of all other steps is nonrelevant, because the whole 
process is disabled.  
 
 
1.4 Delivery systems for small interfering RNA 
 
Nucleic acids as macromolecules to be delivered to certain cell populations have to 
overcome all single delivery steps described in the last chapter. Carrier systems and 
ideas to overcome these hurdles are pointed out in detail in the following section. 
 
 
1.4.1 Basic scaffolds for nucleic acid delivery 
 
Due to extensive disadvantages of systemic delivery of naked siRNA, starting from 
enzymatic degradation36 over renal clearance, interaction with blood compounds, 
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activation of the immune system37 and the inefficient uptake by target cells,38 many 
approaches of systemic delivery use vehicles. As also known from the field of gene 
delivery, these vehicles can be classified into three major groups, illustrated in 
Fig. 1.3: viruses, liposomes and polycations.39-41 
As natural gene delivery vehicles, viruses are able to deliver their genes to target 
cells. Due to a long term evolution process they are ideally adapted to overcome the 
general problems of delivery. Although viruses are very complex, efficient vehicles, 
they also have limitations for the use as siRNA delivery system. 
In general viruses are targeted to one cell type, thus it is difficult to target a special cell 
population that is no common target of a natural virus. Although work has been 
described, developing methods for genetic and chemical de-/retargeting,42-43 reaching 
certain cell populations without cross reactivity remains a challenge. 
 
A                                      B                        C
 
Fig. 1.3 Overview of basic types of carrier-systems for nucleic acid delivery. A: Virus, 
B: Liposome, C: Polycation. 
 
As viruses have been modified and adapted in an evolutive manner for millions of 
years, same did the immune defence of the organisms. Thus viral delivery in general 
is restrained by recognition by the immune system, during the blood circulation as well 
as during cell entrance.44 Therefore the virus has to be genetically or chemically 
modified to avoid an immune response.45 The most prominent disadvantage of viral 
systems for siRNA delivery is the lack of compatibility. For gene delivery the gene of 
interest is introduced into a plasmid. A special packaging cell line is transfected with 
this plasmid, leading to the amplification of the DNA and incorporation into intracellular 
produced viruses. The virus can be isolated out of the medium and used for delivery.46 
siRNA is a completely chemically synthesized structure. Thus it is impossible to get it 
into a virus by the described in vitro virus production method. To obviate this problem, 
DNA has been packed into viral particles such as AAV vectors, bearing a sequence 
encoding for the sense and antisense strand separated by a short nontargeting region 
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called loop.47-48 When the transgene is transcribed in the target cell after transfection, 
it produces mRNA that can self assemble to a double stranded RNA with high 
similarity to siRNA (small hairpin RNA, shRNA). This method bears common 
disadvantages of DNA delivery, because it often is associated with the integration of 
the nucleic acid into the cell genome and thus can hardly be controlled when 
introduced once.49-50  
To circumvent the numerous disadvantages of viral delivery, synthetic structures have 
been designed.51 These so called artificial viruses overcome the hurdles of delivery by 
mimicking viral processes, but avoid their negative aspects. Two major classes of 
vehicles have been developed: liposomes and polyplexes. Besides of them, a various 
amount of different systems combining parts of both vehicle types like lipoplexes,52 
cationic lipids,53 lipidoids,54 etc. have been designed. 
Liposomes are small particles composed of one or several lipid bilayers that entrap a 
hydrophilic core. Multilamellar liposomes originate spontaneously by mixing a 
hydrophobic with a hydrophilic phase. Further treatment e.g. extrusion or sonication 
result in unilamellar vehicles. Drugs can be integrated into this carrier system either in 
the hydrophilic inner compartment or the hydrophobic layer. Liposomes build very 
stable particles and remain stable during the delivery process. In case of siRNA 
deliver, the payload is in the inner, hydrophilic compartment. The delivery process 
after reaching the target cell can be performed in two different manners. The first, less 
frequent option is the fusion of the liposome with the target cell, releasing the siRNA 
into the cytosol. The second, more frequent option includes endocytosis of the 
liposome into an endosome. The endosomal escape then takes place by either 
membrane fusion or endosome disruption. Most trials using lipid formulations for 
nucleic acid delivery address liver cells or liver tumors for therapy. As the liver shows 
high affinity to lipidic particles, they are very efficient in this tissue. This advantage in 
liver targeting displays a disadvantage in the treatment of other tissues. As liposomes 
and other hydrophobic particles are easily directed to the liver, they need a strong 
shielding to get efficiently into other tissues.55 
In contrast, polyplexes are particles that are formed spontaneously by mixing anionic 
and cationic structures under aqueous conditions.56 Due to ionic interactions they 
aggregate in a controlled way (depending on the mixing ratio), resulting in compact 
structures. In case of pDNA or siRNA, building the anionic fraction, different types of 
polycationic polymers have been used to form polyplexes for the delivery process. 
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Linear structures like poly-lysine (PLL),57 linear polyethylenimine (LPEI),58 chitosan59 
or branched structures like polyamidoamine (PAMAM),60 branched polyethylenimine 
(brPEI)61 or polypropylenimine (PPI)62 have been used in several described 
experiments (Fig 1.4). 
 
 
Fig. 1.4 Polycationic polymers for nucleic acid delivery. A: Poly-lysine (PLL), B: linear 
polyethylenimine (LPEI), C: chitosan, D: branched polyethylenimine (brPEI), E: polyamidoamine 
(PAMAM), F: polypropylenimine (PPI). 
 
As pointed out in Fig. 1.4 most used structures are based on a polyamine backbone, 
giving the needed positive charge at physiological pH. As gold standard for the 
delivery of nucleic acids LPEI has been used in several experimental settings.63-65 
This molecule bears many advantages during the delivery process. Once mixed with 
the nucleic acid, it builds stable polyplexes under physiological conditions. These 
polyplexes in general have a positive zeta potential due to the excess of positive 
charged polymer. This enables the attachment to the target cell surface via ionic 
interactions, followed by endocytosis. In the endosome, PEI leads to an escape via 
the so called ‘proton sponge effect’.66-67 Due to its strong buffering capacity, the 
polycation hampers the acidification of the endosome. Thus more and more protons 
get into the endosomal compartment, followed by chloride as counter ion. This leads 
to a strong osmotic pressure, resulting in an influx of water. If the osmotic pressure is 
to strong, the endosome bursts and releases the polyplex into the cytosol.67 However 
PEI like particles have been described that do not have a good transfection 
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efficiency.68 It also seems to be important that the polycationic charge is presented on 
the surface for interaction and destabilization of the endosomal membrane in addition 
to the proton sponge effect.69 Many hurdles during the delivery process can be 
overcome by simple polyplex formation. Standard PEI is a very inefficient carrier for 
siRNA in vitro.70 Aigner et al. however demonstrated efficient delivery in a mouse 
model in vivo.71 Beside this obscurity, many problems occur during in vitro as well as 
in vivo delivery. The introduction of polymeric, charged structures into the cell led in 
many cases to strong toxic side effects. The cell can not degrade the high molecular 
weight polymers, which results in accumulation and interactions with DNA, proteins 
and membranes.72 In vivo the strong positive charged polyplexes interact with 
compounds of the blood circulation, resulting in strong aggregation and thus toxicity. 
Without modification they might interact with every cell they pass by unspecific cell 
attachment, leading to undesired side effects. On the other hand, for example 
succinylation of PEI to block some of the positive polymer charges has resulted in an 
efficient siRNA carrier with strongly reduced cytotoxicity61  
It could be shown that with proper modifications nonviral carrier systems may have 
tremendous advantages over viral systems.51 Although they have many side effects 
and are less efficient, they bear the potential to deliver nucleic acids to cells and have 
the advantage of a huge design space. To reduce side effects and raise efficiency 
new concepts, based on these scaffolds have been developed. 
 
 
1.4.2 Design of multifunctional carrier systems 
 
The different basic types of artificial carrier systems, with their limitations as described 
in the last section can presumably just act as scaffold for an efficient multifunctional 
siRNA carrier system. Compared with a viral delivery vehicle, they just build the ‘inner 
core’. Reducing side effects and raising specificity of synthetic carrier systems was 
obtained in further studies, using more complex functionalized structures attached to 
these scaffolds.73 Modifications and structures, addressing every delivery step are 
pointed out in the following section.  
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1.4.2.1 Stabilization 
 
Stabilization of the carrier system is a key issue especially in case of polyplex 
mediated siRNA delivery. Use of high-molecular weight polycationic polymers used for 
delivery may increase stability of polyplexes, but also triggers high toxicity due to 
cellular accumulation processes, leading to aggregation of intracellular compounds. In 
contrast short fragments (e.g. oligoethylenimine (OEI)) show a dramatically decreased 
toxicity, but also do not build stable polyplexes. A combination of both structures 
giving high stability of the polyplex by reduction of toxicity would result in a favourable 
polymer. Thus linker structures have been introduced into the polycationic backbone 
either pre- or post-polyplex formation. These linkers crosslink short polymers, resulting 
in high molecular weight structures with increased polyplex stability. To reduce the 
toxicity of these huge structures, bioreversible linkers have been used. These linkers 
degrade, reacting on the intracellular environment.62, 74-75 Thus high molecular weight 
structures are cleaved into several small molecules after the payload has been 
delivered. Hence toxicity is strongly reduced. Used linkers include (i) disulfides, 
reacting on the reductive cytosolic environment,76 (ii) acetal linkers cleaved under 
acidic endosomal conditions74 or (iii) peptide structures cleaved by peptidases.77 
Besides the mentioned covalent binding, structures resulting in noncovalent 
interactions were internalized to further enhance stability, like hydrophobic domains 
(e.g. fatty acids or tyrosines).78-80 These modifications result in self organizing 
molecules generating highly stable polyplexes. In a different approach siRNA was 
covalently attached to a polymeric delivery vehicle via a disulfide bond to increase the 
stability and avoid the dissociation of carrier system and cargo.57, 81 The resulting 
hybrid led to efficient knockdown while the stability under physiological conditions was 
drastically increased. 
 
 
1.4.2.2 Shielding 
 
Protection of the carrier surface from interactions with blood compounds and 
nontargeted cells is one of the key issues using several delivery systems. All carriers, 
viruses as well as liposome- and polycation based vector systems have the problem of 
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undesired interactions with compounds during blood circulation, resulting in 
aggregation, destabilization or unwanted transfection of nontargeted cells. Thus the 
hydrophobic or charged surface has to be shielded. The most prominent molecule 
used for shielding is poly (ethylene glycol) (PEG).82-84 It is a highly soluble, uncharged 
polymer that prevents molecules from interactions when coupled to it. The covalent 
attachment can be performed either during synthesis, attaching the poly (ethylene 
glycol) via a linker to a free amino or thiol group57, 85 or after loading the carrier (post-
pegylation).86 Apart from PEG, hydroxyethylene starch (HES) or poly(N-(2-
hydroxypropyl)methacrylamide) (pHPMA)87-88 are feasible molecules for shielding. 
Besides hampering the interaction with other molecules or cells, shielding also raises 
the circulation time in the blood flow due to a decreased clearance89 and avoids 
recognition by the liver or the immune system. 
 
 
1.4.2.3 Targeting 
 
An ideally stabilized, shielded particle is able to circulate for an extended time in the 
blood flow without interacting with any cell. Hence a maximal shielded particle is not 
able to interact with the target cell. Thus additional to a shielding domain, a kind of 
‘homing structure’ to the target tissue has to be incorporated into the carrier system. In 
case of tumor targeting, different strategies allow the accumulation in the target tissue. 
Non targeted structures have already shown to work very efficient in case of DNA 
delivery into tumors. This phenomenon can be explained by the enhanced 
permeability and retention (EPR) effect.90 When growing tumors reach a certain size, 
where they are limited in nutrient supply, they recruit their own blood vessels. These 
vessels are functional but not perfect in structure and orientation. They show large 
fenestrations between the endothelial cells, resulting in leakiness.91 Molecules that 
pass these vessels leave the blood circulation by diffusion and migrate into the tumor 
tissue as do the carrier systems. Small molecules diffuse back into the blood flow, 
when the drug concentration decreases. Big molecules, which are hampered in 
migration once they entered the tissue, accumulate there. This passive targeting has 
been a common method in case of tumoral delivery for many systems.92 
A more specific, active targeting is addressing receptors on the cell surface.93 Almost 
all tissues differ in the expression level of certain receptors, making them 
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distinguishable. Thus the incorporation of ligand structures, analogues of them or 
antibodies addressing these receptors enable a specific interaction with the desired 
tissue, while other tissues remain untransfected. 
For the intracellular delivery of siRNA, endocytosis after cell attachment is required. 
Therefore receptors, leading to this process after ligand binding are the once most 
prominently used for delivery issues. In case of tumor targeting the transferrin receptor 
(Tf-R), the epidermal growth factor receptor (EGF-R), the folic acid receptor (FolA-R) 
or integrins (e.g. αvβ3) are the most described structures used for specific targeting.94-
98
 They are highly upregulated in tumor tissue, and lead to endocytosis after ligand 
attachment.99-102 In first experiments the native ligands (transferrin, the epidermal 
growth factor, folic acid, etc.) have been used. Although they are ligands with high 
binding affinity, they lead to very heterogenic structures when coupled to a carrier 
system. Their huge size and limitation in specific coupling, led to the development of 
smaller structures. By phage display several peptidic molecules have been 
investigated for their binding affinity to receptors like the Tf- or the EGF-receptor. The 
resulting peptides B6 (for Tf-R targeting)103 and GE11 (for EGF-R targeting)104 show a 
good binding affinity, while allowing a more defined attachment to the carrier 
system.105 However, often their specificity and affinity to the receptor always remains 
lower than that of the native ligands. Targeting integrin αvβ3 is possible via different 
types of peptide structures containing the amino acid sequence arginine-glycine-
aspartic acid (RGD).106-107 
Additionally, cells can be targeted using antibodies. They are defined structures with a 
specific, high binding affinity. Especially the EGF-receptor has been topic of several 
studies using antibodies to inhibit tumor growth.108-109 As these antibodies fulfil the 
requirements for a good targeting structure, they were used on carriers as well. 
With a Kd of 10-10 M, folic acid is one of the ligands with the highest binding affinity.110 
Its receptor is upregulated in different tumors,111-112 while it is almost absent in other 
tissues113-114 despite of the apical membrane of epithelial cells in the kidney proximal 
tubules115 and activated monocytes and macrophages.116 As small molecule it can be 
attached rather defined to a carrier system. Using the carboxyl function for coupling, it 
can only be attached via its α- or γ-carboxyl group.117-118 A huge disadvantage using 
random coupling conditions is the strong reduction of binding affinity after coupling via 
the α-carboxyl group.119 
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1.4.2.4 Endosomal escape 
 
After cell entrance via endocytosis, the endosomal escape is the last hurdle during the 
delivery process. Although some liposomes with special, systemically not very stable 
lipid composition can fuse with the membrane, endosomal escape remains a 
bottleneck. Polymers like PEI can use the proton sponge effect to avoid lysosomal 
degradation. As a certain amount of polymer is needed within one endosome to 
mediate enough buffering capacity for the proton sponge effect , and not all 
endosomes are acidified with the same efficiency,101 this method of endosomal 
escape is also not optimal. Hence it can be maximized using further strategies. 
Moreover new structures lacking a buffering capacity120 can be tested as feasible 
carrier systems, if combined with endosomolytic agents. To enhance the escape of the 
endosomal compartment, different structures have been developed. One reasonable 
approach is the use of peptides that bear an endosomolytic activity.121 In 1992 
Wagner and colleagues reported a peptide based on the sequence of the amino-
terminus of the influenza virus hemagglutinin for use in gene transfer.122 Permutation 
of the sequence revealed a peptide (Inf7) that is highly lytic at endosomal pH (pH 5.5), 
while it is not lytic at physiological pH (pH 7.4).123 Thus this peptide displays a useful 
tool for endosomal escape. It is non-functional in the extracellular environment and 
does not lead to erythrocyte lysis or toxicity after cell entrance, while it develops a 
highly lytic activity in the endosomal environment. A further peptide used to overcome 
this bottleneck is melittin.124-125 As main substance of bee venom it is highly lytic126 but 
in contrast to Inf7 does not show advantageous pH dependency, causing highest lytic 
potential at neutral pH, thus significant toxicity in the  delivery process.127 Meyer et al. 
could show that the modification of the peptide with dimethylmaleic anhydride 
(DMMAn) leads to a strong reduction of its lytic activity at neutral pH. Due to the acid 
lability of the modification it is cleaved in the endosome, recovering its lytic potential, 
resulting in increased pDNA and siRNA delivery in vitro. 57, 120, 128 Furthermore 
synthetic peptides mimicking natural lytic peptides have been designed. GALA and 
KALA, consisting of the repeating structure glutamic acid (or lysine for KALA)-alanine-
leucine-alanine build a random structure at neutral pH, while forming an amphipathic 
alpha-helix in an acidic environment. These structures are able to interact with lipid 
bilayers, resulting in enhanced endosomal escape.129 The molecules have been 
shown to mediate gene and siRNA delivery either free130 or in combination with a 
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carrier system.131-134 These systems show that charge (of the polymer) as well as a 
certain hydrophobicity of the peptides is required to enhance the endosomal escape. 
Thus the combination of polycationic backbones and fatty acids, having comparable 
properties, has been a further reasonable approach overcoming this crucial step of 
delivery.80, 89 
 
 
1.5 Defined delivery systems 
 
As described in the last sections, an ideal carrier system for siRNA delivery is 
composed of a backbone, a shielding domain, a targeting ligand, an endosomal 
escape domain and further stabilizing molecules. In comparison to first approaches 
using nonmodified polymers, complexity increased exponential in the last years. As 
the main chemistry did not change, the products became very heterogenic and 
undefined, due to different reasons. The polymers used in most strategies (PEI, PLL, 
PEG, etc.) are synthesized using common random polymerization techniques. Thus 
the backbone itself often (e.g. for PEIs) already lacks definition. The attachment of the 
substructures (fatty acids, peptides, proteins, PEG etc.) is performed using linker 
molecules. These are randomly attached to the backbone of the polymer (e.g. to 
amino groups).135-136 After coupling different substructures the polydispersity of the 
molecules in one batch is very high. Hence the exact reproduction of a batch is almost 
impossible, because many factors have influence on the synthesis. Moreover the 
exact determination of the composition is very difficult, because efficient methods like 
RP-HPLC or mass analysis are no feasible methods for this kind of structures. The 
most relevant disadvantage of these structures is the inability to get an exact 
structure-activity relationship. As the polymers are very heterogenic, experiments can 
just give an average result of knockdown efficiency, toxicity, etc. In contrast, defined 
polymers with an exact structure regarding amount and position of attached molecules 
could give very precise data and enable the design of more efficient delivery systems. 
A strategy to overcome these problems is the solid phase supported peptide synthesis 
(SPPS). The method first described by Merrifield et al.137 allows the synthesis of 
defined structures. On solid support, a molecule is synthesized using a high excess of 
educts and washing them away after reaction is completed by a simple filtration step. 
This method was adapted by Hartmann et al.138-139 to synthesize defined polycationic 
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structures. After adaption and modification, this strategy was used in our group to 
synthesize more than 300 molecules combining polycationic, crosslinking and 
hydrophobic properties. The results published by Schaffert et al. reveal that these 
defined structures enable the determination of a highly price structure - activity 
relationship.80 However the design space of this strategy was limited to lipid modified 
polycationic structures up to now. 
 
 
1.6 Aim of the thesis 
 
RNAi is one of the leading techniques, having the possibility to result in efficient drugs 
for an increasing amount of diseases and arises treatment options on targets that 
were undrugable up to now. The crucial limitation in the development of efficient 
pharmaceuticals remains the delivery process. Although many different types of 
feasible chemical carrier systems with a high efficiency have been evaluated in vitro, 
the in vivo delivery process makes new demands on the delivery vehicles. New 
properties and functional domains have to be included during their design. This has 
shown to result in very efficient but very complex and heterogenic structures e.g. 
carrier PLL-PEG-DMMAnMel-ss-siRNA published by Meyer et al. from our group.57 
The use of very polydisperse, polymeric scaffolds for the synthesis in combination with 
the high degree of functionalization makes the resulting delivery system a very 
heterogenic product. This fact displays an own limitation in the development of 
efficient delivery systems: 
Resulting polymers make an analysis of structure as well as purity of the carrier 
system with state-of-the-art analytics impossible. Achieved physicochemical and 
biological data give just an average of effects of the heterogenic mixture, eliminating 
the determination of a clear structure activity relationship. The polydispersity of the 
carrier mixture results in a strong batch dependency and thus a low reproducibility of 
the synthesis. All these aspects are clear disadvantages regarding the development of 
efficient systems as well as their aspired clinical testing, requiring GMP production 
methods. 
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General aim of this thesis was the development of new efficient, polyplex based 
carrier systems containing functional substructures that address all limitations during 
the delivery process including: 
- Polyplex formation and stability 
- Shielding 
- Receptor mediated cell-targeting 
- Endosomal escape 
- Biodegradability and low toxicity 
 
Specific aims were: 
- Generation of monodisperse constructs by solid-phase supported 
synthesis, enabling state-of-the-art analytics and a controllable 
modification. 
- Introduction of functionalities by modifying either the polymeric backbone 
or the siRNA itself, building covalent conjugates. 
- Biophysical and biological characterization of the novel functionalized 
siRNA polyplexes. 
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2 Materials and Methods 
2.1 Material 
 
2.1.1 Water 
Water is defined in this thesis as deionized water with a conductance below 0.06 µS. 
 
2.1.2 Solvents 
Acetonitrile, HPLC grade 
Dichlorormethane, for analysis 
N,N-Dimethylformamide, peptide grade 
Deuterium oxide 
Ethanol, for analysis 
Methanol, for analysis 
Methyl tertiary butyl ether 
n-Hexane 
TFA 
Sigma-Aldrich, Steinheim, Germany 
AppliChem, Darmstadt, Germany 
Iris Biotech, Marktredwitz, Germany 
Sigma-Aldrich, Steinheim, Germany 
Sigma-Aldrich, Steinheim, Germany 
Sigma-Aldrich, Steinheim, Germany 
AppliChem, Darmstadt, Germany 
Sigma-Aldrich, Steinheim, Germany 
Iris Biotech, Marktredwitz, Germany 
 
2.1.3 Chemicals 
Boric acid 
3-Hydroxypicolinic acid 
5,5'-Dithiobis-(2-nitrobenzoic acid) 
Ethylenediaminetetraacetic acid 
Hepes  
3-Hydroxypicolinic acid 
Potassium cyanide (KCN) 
Sodium chloride (NaCl) 
tris(2-Carboxyethyl) phosphine 
Trisma® Base 
 
Sigma-Aldrich, Steinheim, Germany 
Sigma-Aldrich, Steinheim, Germany 
Merck, Darmstadt, Germany 
Sigma-Aldrich, Steinheim, Germany 
Biomol, Hamburg, Germany 
Sigma-Aldrich, Steinheim, Germany 
Merck, Darmstadt, Germany 
VWR, Darmstadt, Germany 
Sigma-Aldrich, Steinheim, Germany 
Sigma-Aldrich, Steinheim, Germany 
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2.1.4 Chemicals for peptide synthesis 
Reactor: 
Syringe reactor (PP reactor with PE frit) 
 
Resins: 
2-Chlorotrityl chloride resin  
   (200-400 mesh, 1.56 mmol Cl-/g resin) 
Ala-Wang resin (0.35 mmol/g) 
 
Natural amino acids (all L-type): 
Boc-Cys(Trt)-OH 
Dde-Lys(Fmoc)-OH 
Fmoc-Cys(Trt)-OH 
Fmoc-Ser(tBu)-OH 
Fmoc-Lys(Fmoc)-OH 
Fmoc-Glu(OH)-tBu 
 
Artificial amino acids: 
(S)-5-Azido-2-(Fmoc-amino)pentanoic acid 
N10-(Trifluoroacetyl)pteroic acid 
Fmoc-N-amido-dPEG®24-acid 
Succinoyl-tetraethylenpentamine (Stp) 
 
Reagents: 
1 M ammonium hydroxide solution 
Diisopropylethylamin (DIPEA) 
Hydrazine monohydrate 
1-Hydroxybenzotriazol Hydrat (HoBt) 
Ninhydrine 
Phenol 
Piperidine 
PyBop® 
Pyridine 
 
 
MultiSynthech, Witten, Germany 
 
 
 
Iris Biotech, Marktredwitz, Germany 
Novabiochem, Hohenbrunn, Germany 
 
 
Novabiochem, Hohenbrunn, Germany 
Iris Biotech, Marktredwitz, Germany 
Iris Biotech, Marktredwitz, Germany 
Iris Biotech, Marktredwitz, Germany 
Iris Biotech, Marktredwitz, Germany 
Iris Biotech, Marktredwitz, Germany 
 
 
Sigma-Aldrich, Steinheim, Germany 
Clausen & Kaas, Fraum, Denmark 
Quanta Biodesign, Powell, Ohio 
In-house synthesis140 
 
 
Roth, Karlsruhe, Germany 
Iris Biotech, Marktredwitz, Germany 
Iris Biotech, Marktredwitz, Germany 
Sigma-Aldrich, Steinheim, Germany 
Sigma-Aldrich, Steinheim, Germany 
Sigma-Aldrich, Steinheim, Germany 
Sigma-Aldrich, Steinheim, Germany 
MultiSyntech, Witten, Germany 
Sigma-Aldrich, Steinheim, Germany  
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2.1.5 siRNAs 
Table 2.1 Used siRNA molecules. Small letters: 2’-methoxy-RNA, s: phosphorothioate. These nucleic 
acids were synthesized by the Roche Kulmbach GmbH (now Axolabs GmbH, Kulmbach, Germany). 
siRNA target label sequence
AuAucAuGGccGAcAAGcAdTsdT
UGCUUGUCGGCcAUGAuAUdTsdT
AuGuAuuGGccuGuAuuAGdTsdT
CuAAuAcAGGCcAAuAcAUdTsdT
GGAuGAAGuGGAGAuuAGudTsdT
(Cy7)(NHC6)ACuAAUCUCcACUUcAUCCdTsdT
(C6SSC6)AuAucAuGGccGAcAAGcAdTsdT
UGCUUGUCGGCcAUGAuAUdTsdT
(C6SSC6)AuGuAuuGGccuGuAuuAGdTsdT
CuAAuAcAGGCcAAuAcAUdTsdT
(C6SSC6)ucGAGAAucuAAAcuAAcudTsdT
AGUuAGUUuAGAUUCUCGAdTsdT
(C6SSC6)GGAuGAAGuGGAGAuuAGudTsdT
(Cy5)(NHC6)ACuAAUCUCcACUUcAUCCdTsdT
(Hexynyl)(C6SSC6)AuAucAuGGccGAcAAGcAdTsdT
UGCUUGUCGGCcAUGAuAUdTsdT
(Hexynyl)(C6SSC6)AuGuAuuGGccuGuAuuAGdTsdT
CuAAuAcAGGCcAAuAcAUdTsdT
(Hexynyl)(C6SSC6)GGAuGAAGuGGAGAuuAGudTsdT
(Cy5)(NHC6)ACuAAUCUCcACUUcAUCCdTsdT
siAHA1-Cy7 AHA1* Cy7
  siGFP eGFP-Luc ---
  siCtrl --- ---
  C6-ss-C6-siGFP
  C6-ss-C6-siCtrl
 C6-ss-C6-siEG5
  C6-ss-C6-siAHA1-Cy5
  Hexynyl-ss-C6-siGFP
  Hexynyl-ss-C6-siCtrl
  Hexynyl-ss-C6-siAHA1-Cy5
eGFP-Luc
---
EG5 / KSP
AHA1*
eGFP-Luc
---
AHA1*
---
---
Cy5
---
---
---
Cy5
 
 
 
2.1.6 Polycations 
Table 2.2 Used defined polycations.140 
polymer ID structure type protonable amines molecular weight [Da]
46 C-Stp3-C-K-OleA2 i-shape 9 1695
49 C-Stp2-K(K-OleA2)-Stp2-C t-shape 13 2095
76 C-Stp-K(K-OleA2)-Stp-C t-shape 7 1552
229 C-Stp3-C-K-LinA2 i-shape 9 1691
230 C-Gtp-Gtt-Stp-C-K-LinA2 i-shape 8 1676
386 C-Stp3-K(Stp3-C)2 three arm 27 2860
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2.1.7 Peptides 
Inf 7: H2N-GLFEAIEGFIENGWEGMIDGWYGC-amide, Biosyntan (Berlin, Germany) 
 
2.1.8 Cell culture 
All cell culture consumables (dishes, well plates, t-flasks) were purchased from NUNC, 
Langenselbold, Germany) or TPP (Trasadingen, Switzerland). Growth media and 
additives (FCS, Glutamine, Penicillin/Streptomycin) were purchased from Invitrogen 
(Karlsruhe, Germany). Cells were ordered at the american type culture collection 
(ATCC, Wesel, Germany). Used cell lines are listed in table 2.3. 
 
Table 2.3 Used cell lines. 
name description ATCC-Nr. medium
Neuro2A Wildtype murine neuroblastoma cells CCL-131 DMEM
Neuro2A-Luc Murine neuroblastoma cells expressing
 the eGFP-Luciferase fusion gene --- DMEM
KB Wildtype human nasopharyngeal
epidermoid carcinoma cells CCL-17 RPMI, w/o folic acid
KB-Luc Human nasopharyngeal epidermoid carcinoma 
cells expressing the eGFP-Luciferase fusion gene --- RPMI, w/o folic acid
 
 
 
2.2 Methods 
 
2.2.1 Loading of a 2-chlorotrityl chloride resin 
 
All chemical syntheses were performed using either a preloaded Wang-resin or 2-
chlorotrityl chloride-resin (CTC-resin, 200-400 mesh, Iris Biotech, Marktredwitz). For 
stability reasons, the CTC-resin was loaded immediately prior to use. 
The resin (1.56 mmol chloride/g) was swollen in anhydrous DCM for 10 min. 
0.45 eq./g (150% of the desired loading) of the Fmoc protected amino acid per gram 
resin and DIPEA (0.9 eq./g) were dissolved in anhydrous DCM, added to the resin and 
mixed for 1 h. After coupling, a mixture of DCM/MeOH/DIPEA (80/15/5; v/v/v) was 
added for 30 min to cap residual reactive chloride groups.  
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Do determine the resin loading, a small amount of resin (~5 mg) was washed twice 
with DCM and two times with n-hexane and dried under vacuo. 1 mg dry resin 
(triplicates) was mixed with 1 ml 20% (v/v) piperidine in DMF and incubated for 1 h. 
The cleaved Fmoc-protection group was quantified, measuring the adsorption at 
301 nm. The loading was calculated using following equation: 
 
Dmgm
A
gmmolloading
××
×
=
7800][
1000]/[ 301  
 
where D is the dilution factor. After determination of the resin loading, the complete 
resin was incubated four times for 10 min with 20% (v/v) piperidine in DMF, washed 
three times with DMF, three times with DCM, three times with n-hexane and dried 
under vacuo. 
 
 
2.2.2 General solid phase supported peptide synthesis procedure 
 
Solid phase based peptide synthesis was used in this thesis to generate peptide 
ligands, defined carriers and targeted structures for siRNA delivery. Common Fmoc 
based synthesis first published by Merrifield et al.137 was performed. As solid support 
either Wang- or 2-chlorotrityl chloride resin was used. The desired amount of resin 
was filled into a syringe reactor of appropriate size (2 mL, 5 mL, 10 mL, PP reactor 
with PE frit, Multisynthech, Witten, Germany) and fixed on a vacuum station. The 
general synthesis procedure was performed as described in table 2.4. After reaction 
and washing steps, solvents and non reacted reagents were removed by vacuum 
filtration. 
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Table 2.4 General synthesis protocol. 
Step Nr.  Description V [mL/g resin] Time [min]
1 20% piperidine/DMF 10 4 x 10 min
2 DMF wash 10 5 x 1 min
3 AA/PyBop/HoBt/DIPEA4/4/4/8 eq. In DMF/DCM (1/1) 10 1 x 60 min
4 DMF wash 10 5 x 1 min
5 DCM wash 10 5 x 1 min
6 Kaisertest 10
 
 
 
2.2.3 Kaiser test 
 
The Kaiser test was used as in process control to detect free amino groups on the 
resin and thus to determine if the attachment of a building block has been completed. 
For that purpose a few resin beads were taken out of the reactor, filled in an 
Eppendorf tube and washed three times with 1 mL methanol. After the solvent has 
been removed, 2 drops of each of the following solutions were filled into the reaction 
tube, 5% ninhydrine in EtOH (w/v), 80% phenol in EtOH (w/v) and KCN in pyridine 
(2 mL 0.001 M KCN in 98 mL pyridine). The mixture was incubated in a heating block 
at 100°C for 4 min. An intense blue color indicated  free amine residues. 
 
 
2.2.4 Synthesis of FolA-PEG24-K-(Stp4-C)2 and its analogues 
 
After swelling Cys(Trt)-NH2 loaded 2-chlorotrityl chloride resin (0.1 mmol, 
0.35 mmol/g) in DCM for 30 min, the backbone was synthesized with succinoyl-
tetraethylenpentamine (Stp) as building block. First 4 Stp units were attached, using 
the coupling conditions described under 2.5.2. After the Fmoc-protection group of the 
fourth Stp unit was cleaved, Dde-Lys(Fmoc)-OH was coupled as branching domain. 
The coupling of 4 further Stp units was performed on the lysine side chain, using 
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standard reaction conditions. After removal of the last Fmoc-protection group Boc-
Cys(Trt)-OH was attached as last amino acid to finish the backbone HO-C(Trt)-Stp4-
K(Stp4-C(Trt)-Boc)-Dde. The Dde protective group was removed with 2% hydrazine 
monohydrate in DMF (v/v) (10-30 times for 5 min) until no significant absorption at 
300 nm was measurable in the supernatant of the deprotection mixture. In between 
the deprotection steps the resin was washed twice with DMF. Fmoc-PEG24-OH 
dissolved in 1 mL DCM/DMF (1/1, v/v) was added under standard coupling conditions. 
The vessel was agitated until Kaiser test indicated complete conversion. After Fmoc 
cleavage, Fmoc-Glu(OH)-tBu and N10-(Trifluoroacetyl)pteroic acid were attached in 
additional steps. The resin was washed 5 times with DMF and 5 times with DCM, 
before the TFA group was removed, incubating the resin with 1 M ammonium 
hydroxide/DMF (1/1, v/v) four times for 30 min. In between the cleavage steps, the 
resin was washed with DCM. After completion of the reaction the resin was washed 
three times with DCM, three times with n-hexane and dried for 12 h over KOH in 
vacuo. The peptidic structure was cleaved of the resin by suspending it in a solution of 
TFA/H2O/TIS (95.0/2.5/2.5, v/v/v) and incubated for 2 h. The cleavage solution was 
collected by filtration. To increase the yield, the resin was washed twice with TFA and 
once with DCM. After concentrating the flow-through by evaporation, the solution 
(approx. 1 mL) was dropped slowly in a 1/1 mixture (v/v, 40 ml) of cooled (0°C) MTBE 
and n-hexane. The resulting precipitate was centrifuged at 4°C for 10 min and 2000-
3000 rpm. The solvents were decanted and the pellet was washed twice with ice-cold 
MTBE. The resulting pellet was dissolved in 50% (v/v) acetonitrile in water and 
lyophilized. 
A structural analogue bearing serines instead of cysteines was synthesized in an 
analogues procedure using Ser(tBu)-NH2 loaded CTC-resin. The backbone was 
terminated with Boc-Ser(tBu)-OH instead of Boc-Cys(Trt)-OH.  
 
 
2.2.5 Synthesis of A-PEG24-K-(Stp4-C)2 and its analogues 
 
After swelling Ala-Fmoc loaded wang resin (0.1 mmol, 0.35 mmol/g) in DMF over 
night, the resin was washed 3 times with DCM. After removing the Fmoc protection 
group under standard conditions Fmoc-PEG24-OH and Fmoc-Lys(Fmoc)-OH were 
attached consecutively using the under 2.2.2 described coupling procedure. After 
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subsequent removal of the protection group four Stp units were attached to each 
amine of the branching lysine. For this purpose the coupling protocol was modified. 
The used ratio of AA/PyBop/HOBt/DIPEA was set to 8/8/8/16 based on resin bound 
polymer, resulting in the common 4/4/4/8 ratio per free amine. After the Stp coupling 
step was repeated 4 times Boc-Cys(Trt)-OH was attached using the modified protocol 
to finish the synthesis. The resin was washed three times with DCM, three times with 
n-hexane and dried for 12 h in vacuo. To cleave the peptidic structure, the resin was 
suspended in a solution of TFA/H2O/TIS (95.0/2.5/2.5, v/v/v) for 2 h. The cleavage 
solution was collected by filtration and the resin washed twice with TFA and once with 
DCM. After concentrating the product by evaporation, the solution (approx. 1 mL) was 
dropped slowly in a mixture of cooled (0°C) MTBE an d n-hexane (1/1, v/v, 40 ml). The 
resulting precipitate was centrifuged at 4°C for 10  min (2000-3000 rpm). The solvents 
were decanted and the pellet was washed twice with ice-cold MTBE. The resulting 
precipitate was dissolved in 50% (v/v) acetonitrile in water and lyophilized. Structural 
analogues lacking the PEG chain were synthesized the same way. 
 
 
2.2.6 Synthesis of FolA-PEG24-C 
 
After swelling Cys(Trt)-NH2 loaded 2-chlorotrityl chloride resin (0.1 mmol, 
0.35 mmol/g) in DCM for 30 min, Fmoc-PEG24-OH, Fmoc-Glu(OH)-tBu and 
N10-(Trifluoroacetyl)pteroic acid were attached consecutively, using the standard 
synthesis protocol. After washing the resin five times with DMF and five times with 
DCM, the TFA group was removed, incubating the resin with 1 M ammonium 
hydroxide solution/DMF (1/1, v/v) four times 30 min. In between the cleavage steps 
the resin was washed with DCM. After completion of the reaction the resin was 
washed three times with DCM, three times with n-hexane and dried for 12 h in vacuo. 
The peptidic structure was cleaved from the resin, suspending it in a solution of 
TFA/H2O/TIS (92.5/2.5/2.5, v/v/v) for 2 h. The cleavage solution was collected by 
filtration and the resin washed twice with TFA and once with DCM. After concentrating 
the product by evaporation, the solution (approx. 1 mL) was dropped slowly in a 1/1 
mixture (v/v, 40 ml) of cooled (0°C) MTBE and n-hex ane. The resulting precipitate was 
centrifuged at 4°C for 10 min (2000-3000 rpm). The solvents were decanted and the 
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pellet was washed twice with ice-cold MTBE. The resulting pellet was dissolved in 
50% (v/v) acetonitrile in water and lyophilized. 
 
 
2.2.7 Synthesis of FolA-PEG24-Azide 
 
After swelling (S)-5-Azido-2-(amino)pentanoic acid loaded 2-chlorotrityl chloride resin 
(0.1 mmol, 0.35 mmol/g) in DCM for 30 min, Fmoc-PEG24-OH, Fmoc-Glu(OH)-tBu and 
N10-(Trifluoroacetyl)pteroic acid were attached consecutively, using the standard 
synthesis protocol described under 2.2.2. After washing the resin five times with DMF 
and five times with DCM, the TFA group was removed, incubating the resin with 1 M 
ammonium hydroxide solution/DMF (1/1, v/v) four times 30 min. In between the 
cleavage steps the resin was washed with DCM. After completion of the reaction the 
resin was washed three times with DCM, three times with n-hexane and dried for 12 h 
over KOH in vacuo. The peptidic structure was cleaved of the resin by suspending it in 
a solution of TFA/H2O/TIS (95.0/2.5/2.5, v/v/v) for 2 h. The cleavage solution was 
collected by filtration and the resin washed twice with TFA and once with DCM. After 
concentrating the product by evaporation, the solution was dropped slowly in a 1/1 
mixture (v/v, 40 ml) of cooled (0°C) MTBE and n-hex ane. The resulting precipitate was 
centrifuged at 4°C for 10 min (2000-3000 rpm). The solvents were decanted and the 
pellet was washed twice with ice-cold MTBE. The resulting pellet was dissolved in 
50% (v/v) acetonitrile in water and lyophilized. 
The structural analogue PEG24-Azide was synthesized the same way, cleaving the 
peptide off the resin after addition of Fmoc-PEG24-OH and removing its protection 
group. 
 
 
2.2.8 Synthesis of the endosomolytic Inf7-siRNA hybrid 
 
For the synthesis of Inf7-siRNA, siRNA with a C6-s-s-C6 modification at the 5’-end of 
its sense strand was used. In a typical experiment 500 nmol siRNA was diluted in 
400 µl water and incubated for 30 min with 10 eq. tris(2-carboxyethyl)phosphine 
(TCEP) to cleave the disulfide bridge and remove the protection group. To remove 
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TCEP and the cleaved C6-SH fragment, the HS-C6-siRNA was purified by ion 
exchange chromatography using a 1 mL ResourceQ column connected to an Äkta 
basic system, detecting at 260 nm. The column was equilibrated with buffer A 
containing 20 mM Hepes, 10 mM NaCl, pH 6.5, 30% (v/v) acetonitrile. Same buffer 
was used to load the sample onto this column. After the monitored detection 
wavelength had reached baseline, HS-C6-siRNA was eluted, applying a sodium 
chloride gradient of 10 mM/min and a flow rate of 1 mL/min. 
To enable the attachment of the Influenca peptide (Inf7, Sequence: 
H2N-GLFEAIEGFIENGWEGMIDGWYGC-amide123) via its free thiol group, the siRNA 
was activated using 20 eq. of 2,2’-dinitro-5,5’-dithio-dibenzoic acid (DTNB) diluted in 
200 µL buffer containing 20 mM Hepes pH 8.0. The siRNA solution was added 
dropwise to avoid dimerization. After 30 min incubation the mixture was diluted 2:1 
with buffer containing 20 mM Hepes, pH 6.5, 30% (v/v) acetonitrile. The resulting 
product (TNB-s-s-C6-siRNA) was purified under the same conditions as described for 
HS-C6-siRNA. Attachment of Inf7 was performed, mixing 1.5 eq. of the peptide, diluted 
in 500 µL 20 mM Hepes pH 8.5, 30% (v/v) acetonitrile with 1 eq. of the activated 
siRNA. After 2 h incubation at RT, the sample was diluted 2:1 with buffer A. 
Purification of the resulting Inf7-siRNA was performed on a 1 mL ResourceQ column 
connected to an Äkta basic system, detecting at 260 nm. The column was equilibrated 
with buffer A. Same buffer was used to load the sample onto this column. After the 
monitored detection wavelength had reached baseline, the column was washed using 
buffer A containing 200 mM NaCl. Inf7-siRNA was eluted setting a gradient of 10 mM 
NaCl/min and a flow rate of 1 mL/min. Resulting fractions (0.5 mL) were analyzed 
using analytical agarose gel electrophoresis. Samples containing gel-retarded siRNA 
compared to unmodified control were pooled. Concentration and buffer exchange for 
in vivo studies was performed, using a Centrifugal filter unit (Amicon Ultra, MWCO: 
10000 Da, Millipore, Carrigtwohill, Ireland). 
 
 
2.2.9 Synthesis of the nonreducible control Inf7-Mal-siRNA 
 
For the synthesis of Inf7-Mal-siRNA, siRNA with a C6-s-s-C6 modification at the 5’-end 
of its sense strand was used. In a typical experiment 500 nmol siRNA was diluted in 
400 µl water and incubated for 30 min with 10 eq. tris(2-carboxyethyl)phosphine 
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(TCEP) to cleave the disulfide bridge and remove the protection group. To remove 
TCEP and the cleaved C6-SH fragment, the HS-C6-siRNA was purified by ion 
exchange chromatography using a 1 mL ResourceQ column connected to an Äkta 
basic system, detecting at 260 nm. The column was equilibrated with buffer A 
containing 20 mM Hepes, 10 mM NaCl, pH 7.4, 30% (v/v) acetonitrile. Same buffer 
was used to load the sample onto this column. After the monitored detection 
wavelength had reached baseline, HS-C6-siRNA was eluted, applying a sodium 
chloride gradient of 10 mM/min and a flow rate of 1 mL/min. 
To connect the thiol modified siRNA with the thiol modified Inf7 peptide by a 
noncleavable linkage, the linker bis-maleimide-PEG2 (BM-PEG2, Thermo Scientific, 
Rockford, IL) was used. 3.1 mg linker (20 fold excess per HS-C6-siRNA) was 
dissolved in 500 µl DMSO and mixed with the purified, deprotected siRNA. After 
30 min incubation at RT, the resulting product (Mal-s-C6-siRNA) was purified under 
same conditions as described for HS-C6-siRNA. Attachment of Inf7 was performed, 
mixing 1.5 eq. of the peptide, diluted in 500 µL 20 mM Hepes pH 8.5, 30% (v/v) 
acetonitrile with 1 eq. of the activated siRNA. After 2 h incubation at RT, the sample 
was diluted 2:1 with buffer A. Purification of the resulting Inf7-Mal-siRNA was 
performed on a 1 mL ResourceQ column connected to an Äkta basic system, 
detecting at 260 nm. The column was equilibrated with buffer A. Same buffer was 
used to load the sample onto this column. After the monitored detection wavelength 
had reached baseline, the column was washed using buffer A containing 200 mM 
NaCl. Inf7-Mal-siRNA was eluted, setting a gradient of 10 mM NaCl/min and a flow 
rate of 1 mL/min. Resulting fractions (0.5 mL) were analyzed using analytical agarose 
gel electrophoresis. Samples containing gel-retarded siRNA compared to unmodified 
control were pooled. 
 
 
2.2.10 Synthesis of the targeted FolA-PEG24-ss-siRNA hybrid 
 
For the synthesis of FolA-PEG24-ss-siRNA, siRNA with a C6-s-s-C6 modification at the 
5’-end of its sense strand was used. In a typical experiment 500 nmol siRNA was 
diluted in 400 µl water and incubated for 30 min with 10 eq. tris(2-
carboxyethyl)phosphine (TCEP) to cleave the disulfide bridge and remove the 
protection group. To remove TCEP and the cleaved C6-SH fragment, the 
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HS-C6-siRNA was purified by ion exchange chromatography using a 1 mL ResourceQ 
column connected to an Äkta basic system, detecting at 260 nm. The column was 
equilibrated with buffer A containing 20 mM Hepes, 10 mM NaCl, pH 6.5, 30% (v/v) 
acetonitrile. Same buffer was used to load the sample onto this column. After the 
monitored detection wavelength had reached baseline, impurities were eluted using 
buffer A containing 200 mM NaCl. The elution of the product HS-C6-siRNA was 
performed applying a sodium chloride gradient of 10 mM/min and a flow rate of 
1 mL/min. 
To enable the attachment of the targeting structure via its free thiol group, the siRNA 
was activated using 20 eq. of 2,2’-Dinitro-5,5’-dithio-dibenzoic acid (DTNB) diluted in 
200 µL buffer containing 20 mM Hepes pH 8.0. The siRNA solution was added 
dropwise to avoid dimerization. After 30 min incubation the mixture was diluted 2:1 
with buffer containing 20 mM Hepes, 30% (v/v) acetonitrile. The resulting product 
(TNB-s-s-C6-siRNA) was purified under the same conditions as described for HS-C6-
siRNA. Attachment of FolA-PEG24-C was performed, mixing 1.5 eq. of the peptide, 
diluted in 500 µL 20 mM Hepes pH 8.5, 30% (v/v) acetonitrile with 1 eq. of the 
activated siRNA. After 2 h incubation at RT, the sample was diluted 2:1 with buffer A. 
Purification of the resulting FolA-PEG24-s-s-siRNA was performed on a 1 mL 
ResourceQ column connected to an Äkta basic system, detecting at 260 nm. The 
column was equilibrated with buffer A. Same buffer was used to load the sample onto 
this column. After the monitored detection wavelength had reached baseline, the 
column was washed using buffer A containing 200 mM NaCl. siRNA was eluted 
setting a gradient of 10 mM NaCl/min and a flow rate of 1 mL/min. Resulting fractions 
(0.5 mL) were analyzed using analytical agarose gel electrophoresis. Samples 
containing gel-retarded siRNA compared to unmodified control were pooled. 
 
 
2.2.11 Synthesis of siRNA hybrids via copper(I) catalyzed 1,3-dipolar 
cycloaddition 
 
To enable the attachment of a targeting structure via copper(I) catalyzed 1,3-dipolar 
cycloaddition, siRNA modified with a hexynyl-ss-C6-linker at the 5’-end of its sense 
strand was used. In a typical experiment 74 nmol siRNA dissolved in 100 µL H2O was 
mixed with 296 nmol FolA-PEG24-Azide in 300 µL DMSO/tertiary butanol (3/1; v/v) and 
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60 µL TBTA/CuBr solution (0.1 M TBTA/0.1 M CuBr 2/1 (v/v) each in DMSO/tertiary 
butanol (3/1 (v/v)) and incubated for 3 h at 37°C u nder constant shaking. To remove 
precipitates, the solution was diluted with 1.5 mL buffer A (20 mM Hepes, pH 6.5, 30% 
acetonitrile) and centrifuged for 5 min at 13000 rpm. The reaction product was purified 
using a 1 mL ResourceQ column connected to an Äkta basic system, detecting at 
260 nm. The column was equilibrated with buffer A containing 20 mM Hepes, 10 mM 
NaCl, pH 6.5, 30% (v/v) acetonitrile. Same buffer was used to load the sample onto 
this column. After the monitored detection wavelength had reached baseline, the 
column was washed using buffer A containing 200 mM NaCl. FolA-PEG24-click-siRNA 
was eluted setting a gradient of 10 mM NaCl/min and a flow rate of 1 mL/min. 
Resulting fractions (0.5 mL) were analyzed using analytical agarose gel 
electrophoresis. Samples containing gel-retarded siRNA compared to unmodified 
control were pooled. 
 
 
2.2.12 Analytical RP-HPLC 
 
The quantitative analysis of the peptide synthesis products was performed using 
reverse phase high pressure liquid chromatography (RP-HPLC). The used system 
was a Waters 600 controller connected to a Waters 717plus Autosampler and a 
Waters 996 Photodiode Array Detector under control of the Millennium software. As 
analytical column a SunfireTM C18 (5 µm, 4.6 x 150 mm, Waters, Milford, MA) was 
used. 
In a standard procedure the product was diluted using either water containing 0.1% 
(v/v) TFA or a mixture of water and acetonitrile (1/1, v/v) containing 0.1% (v/v) TFA to 
a concentration of 1 mg/mL. 30 µL of this solution was loaded onto the column using a 
water/acetonitrile (0.1% (v/v) TFA) mixture of 95/5 (v/v) and a flow of 1 mL/min for 
5 min. The product was eluted using a water/acetonitrile gradient from 95/5 (v/v) to 
0/100 (v/v) in 20 min. The spectra of detected wavelength ranged between 200 and 
800 nm. 
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2.2.13 MALDI-TOF-MS analysis 
 
2.2.13.1 For peptidic structures 
 
1 mg peptidic structure was dissolved in 1 mL H2O 0.1% (v/v) TFA. 4 µL of this 
solution as spotted on a 4 µL matrix droplet consisting of a saturated solution of 2,5-
dihydroxybenzoic acid (DHB) in 50% (v/v) acetonitrile containing 0.1% (v/v) TFA. 
Samples were analyzed using an Autoflex II mass spectrometer (Bruker Daltonics, 
Bremen, Germany). 50 – 100 spectra of respective probes were averaged for one 
sample spectrum. 
 
 
2.2.13.2 For siRNA hybrids 
 
After purification by ion exchange chromatography (see synthesis) the samples were 
diluted in buffer containing 20 mM Hepes, 500 mM NaCl and 30% (v/v) acetonitrile. As 
ions decrease the quality of a MALDI spectrum the samples were desalted by dialysis. 
For that purpose a 5 µl sample droplet was placed on an ultrafiltration membrane 
(0.2 µm, Millipore, Schwalbach, Germany) swimming in a petri dish filled with water. 
After 2 h incubation 4 µL of the dialyzed solution was spotted on a 4 µL matrix droplet 
consisting of a saturated solution of 3-hydroxy picolinic acid (HPA) in 50% (v/v) 
acetonitrile. Samples were analyzed using an Autoflex II mass spectrometer (Bruker 
Daltonics, Bremen, Germany). 50 – 100 spectra of respective probes were averaged 
for one sample spectrum. 
 
 
2.2.14 1H-NMR 
 
The 1H-NMR spectra were recorded using a JNMR-GX (400 MHz, Joel) with a 
coupling constant of 0.3 Hz. For the measurement 10-15 mg sample was diluted in 
deuterated water. Spectra were analyzed using the NMR software MestreNova 
(MestreLab research). 
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2.2.15 Analytical agarose gel electrophoresis 
 
The analytical agarose gel electrophoresis was used to analyze fractions of the ion 
exchange based siRNA-conjugate purification. As the chromatogram always showed 
different peaks with absorption at 260 nm, product containing fractions were 
determined by gel electrophoresis. 
The analysis was performed using a 2.5% (w/v) agarose gel in TBE buffer (800 mM 
Tris, 3.8 M boric acid, 2 mM EDTA). For staining GelRed (Biotium Inc., Hayward, CA) 
was added to the liquid gel. Standard volumes of 3 µL per fraction of the ion exchange 
purification were mixed with 7 µL water, 5 µl loading dye (30% glycerol, 0.25% 
bromphenol blue in water) and loaded onto the gel. The electrophoresis was 
performed using an electric tension of 100 V for 100 min. 
 
 
2.2.16 Particle formation 
 
Polyplexes for in vitro experiments were formed as follows: 270 ng siRNA (free or 
conjugated) was diluted in 10 µL HBG (20 mM Hepes, 5% (v/v) glucose pH 7.4). The 
desired amount of polymer, calculated as protonable polymer nitrogen / siRNA 
phosphate (N/P 3, 6, 12, 16, 20, 40) was diluted in 10 µL HBG in a separate 
Eppendorf tube. The polycation solution was mixed with the siRNA solution rapidly by 
pipetting up and down 5-10 times. For polyplex formation the mixture was incubated 
for 40 min at RT. 
For in vivo experiments, 50 µg siRNA (free or conjugated) as well as the desired 
amount of polymer were diluted separately in 125 µL HBG for intravenous injection or 
25 µL for intratumoral injection. After mixing the solutions rapidly, it was incubated at 
RT for 40 min to form polyplexes. 
 
 
2.2.17 Gel migration assay 
 
The gel migration assay was performed to determine the particle formation ability of 
polymers and siRNA. Due to ionic interactions between siRNA and polymer, the 
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nucleic acid is encapsulated in polyplexes. The loss of free negative charge and the 
increased size of the particle in comparison to free siRNA hampers its migration into 
the agarose gel. Thus hampered migration is a signal for interactions between nucleic 
acid and polymer. 
The assay was performed in a 2.0% (w/v) agarose gel in TBE buffer (800 mM Tris, 
3.8 M boric acid, 2 mM EDTA). For staining GelRed (Biotium Inc., Hayward, CA) was 
added to the liquid gel. Polyplexes were formed under in vitro conditions as described 
under 2.2.16. After incubation for 40 min and gentle addition of 5 µL loading buffer 
(30% (w/v) glycerol, 0.25% (w/v) bromophenol blue in water) the samples were filled 
into the pockets of the agarose gel. Gel electrophoresis was performed using an 
electric tension of 80 V for 60 min. 
 
 
2.2.18 Size measurement 
 
2.2.18.1 Laser light scattering 
 
The particle size of polyplexes with a diameter above 10 nm were measured by laser-
light scattering using a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, 
U.K.). Polyplexes were formed under in vitro or in vivo conditions as described under 
2.2.16 with following modification: To achieve results the amount of siRNA polymer 
and buffer was increased by the same factor to result in 10 µg siRNA. After polyplex 
formation the solution was gently filled up to 1 mL with 20 mM Hepes, pH 7.4 before 
measurement. Average values were calculated with the data of 10 runs with standard 
deviations. Three experimental replicates were measured. 
 
 
2.2.18.2 Fluorescence correlation spectroscopy (FCS) 
 
The particle size of polyplexes with a diameter below 10 nm were measured by 
fluorescence correlation spectroscopy (FCS) using an Axiovert 200 microscope with a 
ConfoCor2 unit (Carl Zeiss, Jena, Germany). A HeNe laser (633 nm, average power 
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of 50 µW at the sample) was used for excitation. The objective was a 40x (NA = 1.2) 
water immersion approchromate (Carl Zeiss, Jena, Germany). 
Particles were formed under in vitro or in vivo conditions as described under 2.2.16 in 
a volume of 10 µL HBG with a final concentration of 14.8 µM siRNA, including 50 nM 
Cy5 labelled Inf7-siRNA at indicated N/P ratios. After polyplex formation the particles 
were gently filled up with 200 µL HBG, transferred to a eight well LabTek chamber 
slide (NUNC, Wiesbaden, Germany) for measurement. Three experimental replicates 
were measured. These measurements were performed together with Christina 
Troiber. 
 
 
2.2.19 Zeta potential measurement 
 
The measurement of the zeta potential is a method to determine the surface charge of 
a particle or polyplex. Polyplexes were formed under in vitro or in vivo conditions as 
described under 2.2.16 with following modification: To achieve results the amount of 
siRNA, polymer and buffer was increased by the same factor to result in 10 µg siRNA. 
After polyplex formation for 40 min, the solution was gently filled up to 1 mL with 
20 mM Hepes, 1 mM NaCl, pH 7.4. The zeta potential was measured using a 
Zetasizer Nano ZS (Malvern instruments, Worcestershire, U.K.). Average values were 
calculated with the data of 10 runs with standard deviations. Three experimental 
replicates were measured. 
 
 
2.2.20 Erythrocyte leakage assay 
 
In the erythrocyte leakage assay the membrane disruptive activity of compounds was 
explored. For this purpose erythrocytes were chosen as model structure. Disruption of 
the membrane leads to a release of hemoglobin, which can be measured at 
absorption of 405 nm. In relation to an untreated control and complete lyzed cells, the 
relative lytic activity of a compound can be quantified. 
For this purpose fresh citrate treated murine blood was washed with phosphate buffer 
saline (PBS) and centrifuged at 800 g and 4°C for 1 0 min. This procedure was 
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repeated until the supernatant showed no red appearance. After decanting the buffer, 
the erythrocytes were counted and diluted in three different samples with PBS pH 7.4, 
pH 6.5 or pH 5.0 to a concentration of 5 × 107 erythrocytes/mL. The tested structure 
(peptide or siRNA-conjugate) was diluted to a concentration of 10 µM using PBS 
buffer pH 7.4, pH 6.5 or pH 5.0. 75 µL erythrocyte solution was mixed with 75 µL 
structure containing solution in a well of a 96-well V-bottom plate (NUNC, Roskilde, 
Denmark) and incubated at 37°C for 60 min. All mixt ures were prepared in triplicate 
for all three pH ratios. As negative control 75 µL cells were mixed with 75 µL PBS 
buffer, as positive control 75 µL 1% (w/v) Triton X-100 at indicated pH ratios was 
used. After incubation, intact and lyzed blood cells were removed by centrifugation at 
800 g and 4°C for 10 min, 80 µL of the supernatant was transferred into a new 96-well 
plate (TPP 96F, Trasadingen, Switzerland). The amount of released haemoglobin was 
determined, measuring the absorption at 405 nm in a microplate reader (Spectrafluor 
Plus, Tecan Austria GmbH, Grödig, Austria). Three experimental replicates were 
measured. The lysis of erythrocytes was calculated in relation to 100% lysis (Triton 
X-100 treated erythrocytes) and 0% lysis (buffer treated erythrocytes). 
 
 
2.2.21 Fluorescence microscopy 
 
For the qualitative analysis of siRNA uptake, KB cells or Neuro2A cells were seeded 
into 8 well LabTek chamber slides (NUNC, Wiesbaden, Germany), at a density of 
2 x 104 cells/well. After 24 h, culture medium was replaced with 240 µL fresh growth 
medium. 
For the uptake of targeted siRNA 1.5 µg Cy5-labeled nucleic acid was dissolved in 
60 µL HBG, added to each well of the chamber slides and incubated for thirty minutes 
at 37°C. For the uptake of targeted polyplexes, pol yplexes were formed under in vitro 
conditions as explained under 2.2.16 using 200 ng Cy5-labeled siRNA. After polyplex 
formation for 40 min the complexes were added to each well of the chamber slides 
and incubated for 30 min at 37°C.  
After treatment, cells were washed twice with 500 µL PBS. To stain nuclei, Hoechst 
33342 dye (Thermo scientific, Rockford, IL) was added. Cellular uptake was assayed 
by excitation of Cy5 at 635 nm and detection of emission at 665 nm. A Zeiss Axiovert 
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200 fluorescence microscope was used to collect the images. Data were analyzed and 
processed by AxioVision LETM software. 
 
 
2.2.22 Flow cytometric analysis 
 
Fluorescence microscopy was used during this thesis for qualitative determination of 
cell association and cellular uptake of targeted structures and polymers. 
Cells were seeded into 24-well plates at a density of 5 x 104 cells/well. After 24 h, 
culture medium was replaced by 400 µL fresh growth medium. Targeted polyplexes or 
targeted siRNA conjugates (using Cy5 labelled siRNA) were added to each well at a 
siRNA concentration of 200 nM. After incubated at 37°C for 30 min, cells were washed 
twice with PBS, detached with trypsin/EDTA and taken up in PBS containing 10% (v/v) 
FCS. Flow cytometry was performed using a Cyan™ ADP flow cytometer (Dako, 
Hamburg, Germany). Cellular uptake was assayed by excitation of Cy5 at 635 nm and 
detection of emission at 665 nm. To discriminate between viable and dead cells, cells 
were appropriately gated by forward/sideward scatter and pulse width and 
counterstained with DAPI. 1 x 104 gated events per sample were collected. Data were 
recorded by Summit software (Summit, Jamesville, NY, USA) and evaluated by 
FlowJo® software. 
 
 
2.2.23 Reporter gene silencing 
 
To demonstrate RNAi mediated gene silencing, cell lines stably expressing the 
fusiogenic protein eGFP-Luciferase (composed of eGFP and Luciferase) were used. 
In this thesis siRNA directed against eGFP has been transfected. As this siRNA leads 
to the down regulation of the fusiogenic protein, luciferase activity could be used for 
read out. For detection of unspecific silencing effects due to cross reactivity of siRNA 
or toxicity of the carrier system a non-targeting control sequence siCtrl has been 
tested in comparison under same conditions.  
In a typical experiment 5 x 103 cells in 100 µL medium were seeded in a well of a 96 
well plate (TPP, Trasadingen, Switzerland). After incubation for 24 h at 37°C and 5% 
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CO2 the medium was replaced by 80 µL fresh culture medium. Polyplexes were 
formed as explained under 2.2.16 and added to the well. Each polymer nitrogen to 
siRNA phosphate (N/P) ratio has been tested in triplicate. For targeted delivery, the 
medium containing polyplexes was replaced by fresh culture medium after 30 min at 
37°C and 5% CO 2. For reporter gene silencing cells were incubated for additional 48 h 
at 37°C and 5% CO 2. To quantify the knockdown of the eGFP-Luciferase fusion 
protein, the medium was removed, replaced by lysis buffer (Promega, Mannheim, 
Germany) and incubated for 30 min at RT. The luciferase activity in the cell lysate was 
measured using a luminometer (Lumat LB9507 instrument, Berthold, Bad Wildbad, 
Germany). Luciferase light units were detected from 35 µL cell lysate and 10 s 
integration after injection of luciferin. Silencing efficiency was evaluated as percent of 
reduced luciferase activity compared to HBG treated cells. Three experimental 
replicates were measured. 
 
 
2.2.24 Endogenous target silencing 
 
To study the effectiveness of the tested carrier systems, besides the highly 
upregulated artificial transgene eGFP-Luciferase, an endogenous target was used to 
perform silencing experiments. As candidate the kinesin spindle protein (KSP, EG5) 
was chosen. As reported by Judge et al.141 the silencing of this gene leads to a 
characteristic mitotic figure formation, called ‘aster’. 
In a typical experiment 1 x 104 cells in 200 µL medium were seeded in a well of an 
eight well LabTek chamber slide (NUNC, Wiesbaden, Germany). After incubation for 
24 h at 37°C and 5% CO 2 the medium was replaced by 180 µL fresh culture medium. 
Polyplexes containing 1 µg siRNA were mixed as described under 2.2.16 at N/P 16 
and added to the well. After 30 min incubation medium containing polyplexes was 
replaced by fresh culture medium. After 24 h medium was removed, cells washed five 
times with 200 µL PBS and fixed with a 4% paraformaldehyde solution. After staining 
nuclei with DAPI, aster formation was determined, using a Zeiss Axiovert 200 
(fluorescence microscope, Carl Zeiss AG, Germany). 
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2.2.25 Reporter gene expression 
 
For testing certain characteristics (e.g. targeting ability) of the siRNA carrier systems, 
DNA was chosen as model cargo in certain settings, due to similar characteristics, a 
comparable delivery route and a more sensitive read out. As cargo gene, luciferase 
encoded in a plasmid (pCMVLuc, Plasmid Factory, Bielefeld, Germany) was chosen. 
In a typical experimental setting 1 x 104 cells in 100 µL culture medium were seeded 
per well of a 96-well plate (TPP, Trasadingen, Switzerland). After incubation for 24 h 
at 37°C and 5% CO 2, medium was exchanged against 80 µL fresh culture medium. 
Polyplexes were prepared as followed. 200 ng pDNA in 10 µL HBG and polymer at 
different nitrogen to phosphate (N/P) ratios in 10 µL HBG were mixed by pipetting. 
After incubation for 30 min the 20 µL polyplex solution was added to the cells. 
Polyplexes were removed by medium exchange after 30 min and replaced by 90 µL 
fresh medium and 10 µL PBS containing 10 µM chloroquine when indicated. 24 h after 
transfection, medium was replaced by 100 µL lysis buffer (Promega, Mannheim, 
Germany). After 30 min incubation at RT the luciferase activity was determined 
analyzing 35 µL of the lysate in a luminometer (Lumat LB9507 instrument, Berthold, 
Bad Wildbad, Germany). Luciferase light units were recorded from a 10 s integration 
time after luciferin injection. The transfection efficiency was evaluated as relative light 
units (RLU) per 10000 seeded cells. 
 
 
2.2.26 In vivo assays 
 
In vivo assays in mice were performed by Laura Schreiner and Daniel Edinger, 
therefore will be described in detail in their PhD theses (in preparation). As key results 
proofing special characteristic of the carriers are presented here as well, used 
methods are listed in the following section. 
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2.2.26.1 Near infrared imaging of siRNA distribution 
 
5 x 106 KB cells were injected subcutaneously in the neck of female Rj:NMRI-nu 
(nu/nu) mice (Janvier, Le Genest-St-Isle, France). After tumors reached a size of 
100 mm3, polyplexes containing 50 µg Cy7 labelled siRNA at N/P ratio of 16 in 50 µL 
(intratumoral injection) or 250 µL (intravenous injection) HBG were injected. Detection 
was performed using an IVIS Lumina system with Living Image software 3.2 (Caliper 
Life Sciences, Hopkinton, USA). 
 
 
2.2.26.2 Determination of silencing efficiency by aster formation 
 
5 x 106 KB cells were injected subcutaneously in the neck of female Rj:NMRI-nu 
(nu/nu) mice (Janvier, Le Genest-St-Isle, France). After tumors reached a size of 
100 mm3, polyplexes containing 50 µg Inf7-siRNA at N/P ratio of 16 in 50 µL (intra 
tumoral injection) or 250 µL (intra venous injection) HBG were injected 48 h and 24 h 
prior to euthanasia. Tumors were harvested and either embedded in tissueTek, cut 
into 5 µm slices and stained with DAPI or fixed in formalin, embedded in paraffin, cut 
into 4.5 µm slices and stained by hematoxylin and eosin (HE) staining. 
 
 
2.2.26.3 Urine analysis 
 
4 h after systemic administration of siRNA polyplexes or free siRNA into female 
Rj:NMRI-nu (nu/nu) mice (see 2.26.1 and 2.26.2) urine was collected by punctuation. 
Urine samples were analyzed by agarose gel electrophoresis without further dilution 
as described under 2.17. If indicated, 2 µL of a 0.5 M TCEP solution and 2 µL of a 
heparin solution were added.  
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3 Results 
 
Aim of this thesis was the design of highly defined carrier systems for siRNA mediated 
gene silencing in vitro as well as in vivo. These carrier systems should contain 
functional substructures, addressing limitations during the delivery process. This 
includes stabilization in the extracellular environment, specific cell attachment followed 
by endocytosis, endosomal escape and release of the siRNA in the intracellular 
environment. In contrast to already existing, functional macromolecules these carrier 
systems should be synthetically defined, pure structures enabling a precise chemical 
analysis and the study of a clear structure activity relationship. 
 
 
3.1 Enhancing endosomal escape by endosomolytic active siRNA conjugates 
 
The endosomal escape is one of the major bottlenecks during the delivery process of 
siRNA in vitro as well as in vivo. Polyplexes that enter the cell via endocytosis have to 
escape out of the endosome to avoid lysosomal degradation. As described in 
chapter 1.4.2.4 many different strategies are known to enhance the endosomal 
escape. Incorporation of substructures with a high buffering capacity leads in example 
to a process called proton sponge effect. In contrast the introduction of certain 
peptides enhances the endosomal escape by active disruption of the endosomal 
membrane. The incorporation of endosomolytic activity to polyplexes and lipoplexes 
was mainly limited to covalent attachment of functional domains randomly to the 
delivery vehicle. This has two disadvantages: (i) The random attachment leads to an 
undefined product with a low reproducibility but more important (ii) the endosomal 
escape of siRNA, not the carrier polymer is critical for the delivery. The polymer might 
separate from siRNA before endosomal entry / escape. Thus this strategy leads to a 
new limitation for endosomal escape, the polyplex stability. 
To overcome the hurdle of endosomal escape without generating new bottlenecks, it 
was hypothesized that the direct covalent attachment of a lytic peptide to the siRNA 
would enhance its activity due to a highly efficient endosomal escape. In the following 
chapter the synthesis of this peptide siRNA hybrid, its purification, analysis and 
biological evaluation is described. 
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3.1.1 Design and synthesis of an Inf7-siRNA hybrid 
 
The modification of siRNA is difficult, because it can vary its recognition by the RISC 
complex and thus the silencing ability. The influence on the silencing efficiency is 
limited by different factors, including position, type and stability of attachment as well 
as the properties of the attached macromolecule. Thus it was decided to modify the 
siRNA at the 5’-end of its sense strand. This position was thought to be one of the 
least influencing positions regarding reduction of silencing activity. To further avoid an 
unexpected influence of the connected peptide on the siRNA, it was decided to 
conjugate it via a disulfide linkage. Disulfides are known to be cleaved under the 
reductive cytosolic environment, releasing an almost unmodified siRNA. Furthermore 
this linkage enables a simple synthesis and purification strategy. As lytic molecule 
Inf7, a peptide based on the amino-terminus of the influenza virus hemagglutinin was 
chosen. Its strong lytic activity, which is limited to the endosomal environment, is 
described in chapter 1.4.2.4. 
As shown in Fig. 3.1, the synthesis of Inf7-siRNA was divided into three steps, each 
intermitted by a purification step. For conjugation, siRNA with a thiol modification at 
the 5’-end of its sense strand was chosen.  
 
Fig. 3.1 Synthesis of the Inf7-siRNA hybrid. After deprotection of the thiol group and purification by 
ion exchange chromatography, the thiol bearing siRNA was activated with DTNB. Additional purification 
of the product allowed the defined attachment of the cysteine terminated influenza peptide via a 
disulfide bridge. DTNB: 5,5'-dithiobis-(2-nitrobenzoic acid); TCEP: (2-carboxyethyl)phosphine. 
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To avoid dimerization under storage conditions, the thiol group was protected as 
disulfide. Thus the first step was to deprotect the thiol group in a reductive 
environment using tris(2-carboxyethyl)phosphine (TCEP). To form new disulfide 
bridges, TCEP and the cleaved protective group were removed by ion exchange 
chromatography. The next step was the activation of the free thiol group to enhance 
the reactivity for disulfide formation with the peptidic cysteine. Thus the thiol bearing 
siRNA was incubated with 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB). After 
purification of the product by ion exchange chromatography, the last step was the 
conjugation of the influenca peptide (Inf7) via its thiol group at the C-terminal cysteine. 
After attachment, the product was purified by a last ion exchange chromatographic 
step. As shown in Fig. 3.2 a sodium chloride gradient was applied to separate the 
Inf7-siRNA hybrid from free unmodified siRNA. To evaluate synthesis and purification, 
0.5 mL fractions were collected. Identification of fractions containing modified siRNA 
was performed by analysis via an agarose gel electrophoresis (Fig. 3.3). 
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Fig. 3.2 Chromatogram of the ion exchange chromatographic purification of the Inf7-siRNA 
hybrid. After loading the sample onto a ResourceQ column using 20 mM Hepes, pH 6.5, 50 mM NaCl, 
30% acetonitrile the column was washed with the same buffer containing 200 mM sodium chloride. 
Elution of the product was performed applying a gradient of 10 mM NaCl/min and a flow of 1 mL/min 
over 30 min. 1-18: collected fractions. Detection wavelength: 260 nm (black line), 412 nm (dashed line). 
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Fig. 3.3 Agarose gel analysis of the ion exchange chromatographic purification. Fractions, 
collected during ion exchange chromatographic purification of Inf7-siRNA were analyzed in a 2.5% 
agarose gel. 100 V were applied for 100 min. C: control (unmodified siRNA), 1-18: Fractions collected 
during purification. 
 
The chromatogram (Fig. 3.2) shows, that different fractions with absorption at 260 nm 
elute during the purification process. One fraction during the column loading 
(fraction 1), one during the washing step with 20% buffer B (fraction 2) and one during 
the gradient (fractions 3-18). The analysis of the fractions in an agarose gel (Fig. 3.3) 
proved that the first two peaks do not contain detectable amounts of siRNA, while the 
fractions collected during the elution of the third peak (3-18) all contain siRNA. As can 
be seen in the agarose gel, this peak consists of two nucleic acid populations with 
different behaviour in gel migration. Fractions showing retardation compared to a 
control of unmodified siRNA were pooled (Fraction 5-9). To identify them as the 
expected product the sample was analyzed by MALDI-TOF-MS. A representative 
mass spectrum is shown in Fig. 3.4. 
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Fig. 3.4 MALDI-TOF-MS spectrum of Inf7-siGFP. After purification via ion exchange chromatography 
and analysis by agarose gel electrophoresis, the Inf7-siRNA conjugate was identified by mass 
spectrometry. m/z 6663: antisense strand (Calculated mass: 6668 Da); m/z 9691: Inf7-sense strand 
(Calculated mass: 9691). Used matrix: 3-hydroxypicolinic acid (HPA) 
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The mass spectrum reveals that the sample consists only of peptide modified siRNA. 
The two detected peak populations contain the mass peaks of the unmodified 
antisense strand (m/z 6663) and the peptide conjugated sense strand (m/z 9691). 
Additional signals arise from salts of the pure highly charged strands. 
 
This synthesis has been performed with different siRNA sequences, depending on the 
use of the hybrid and the requested read out of the biological system. A complete 
listing of all synthesized structures is given in table 3.1. 
 
Table 3.1 Overview of synthesized versions of Inf7-siRNA hybrids. Small letter: 2’-methoxy 
modified ribonucleic acids. Cy5: Cyanine 5. 
description target gene label sense strand (5'-3')/
antisense strand (5'-3')
Inf7-siGFP eGFP-Luc --- Inf7-SS-C6-AuAucAuGGccGAcAAGcAdTsdTUGCUUGUCGGCcAUGAuAUdTsdT
Inf7-siCtrl --- --- Inf7-SS-C6-AuGuAuuGGccuGuAuuAGdTsdTCuAAuAcAGGCcAAuAcAUdTsdT
Inf7-siEG5 EG5 / KSP --- Inf7-SS-C6-ucGAGAAucuAAAcuAAcudTsdTAGUuAGUUuAGAUUCUCGAdTsdT
Inf7-siAHA1-Cy5 AHA1 Cy5 Inf7-SS-C6-GGAuGAAGuGGAGAuuAGudTsdT(Cy5)ACuAAUCUCcACUUcAUCCdTsdT
 
 
The presented data show that the synthesis of a pure and defined Inf7-siRNA hybrid 
was performed. The synthesis was independent of the siRNA sequence and was 
reproducible as shown in table 3.1. Thus its functionality and behaviour in a biological 
environment had to be explored in further steps. 
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3.1.2 Functional evaluation of the Inf7-siRNA hybrid 
 
Chapter 3.1.1 has proven that the synthesis of the Inf7-siRNA hybrid is possible. What 
remains unclear is the influence of the covalent attachment to the biological activity of 
its substructures. This is topic of the following chapter. 
 
 
3.1.2.1 Influence of covalent siRNA attachment on the lytic activity of the 
influenza peptide 
 
The biological function of the influenza peptide results from its strong, disruptive 
interaction with biological membranes. It had to be proven, that the attachment of a 
negatively charged siRNA with a more than five times higher molecular weight does 
not influence the interaction between membrane and peptide. Thus the lytic activity of 
the peptide-siRNA hybrid was compared to that of free peptide in an erythrocyte 
leakage assay. Erythrocytes were incubated at 37°C with either free Inf7 peptide or 
the peptide-siRNA hybrid under different pH conditions representing the intracellular- 
and cytosolic environment (pH 7.4), the endosomal environment (pH 5.5) and an 
intermediate pH (pH 6.5). Haemoglobin release as indicator for membrane disruption 
was measured. Results are shown in Fig. 3.5. 
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Fig. 3.5 Lytic activity of the Inf7-siRNA hybrid compared to free Inf7 peptide. Erythrocytes were 
incubated with 5 µM free Inf7 peptide (black bars) or 5 µM Inf7-siRNA conjugate (white bars) at 
indicated pH values. After incubation at 37°C for 6 0 min the haemoglobin release was determined. The 
data is presented as relative values compare to complete lysis by treatment with Triton X-100. 
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The activity of free Inf7 peptide at different pH values in the erythrocyte leakage assay 
shows, that its lytic force is pH dependent as described previously.123 At pH 7.4 
(extracellular and cytosolic pH) there is almost no free haemoglobin measurable (3%), 
indicating, that the peptide is inactive at this pH. At pH 6.5 32% free haemoglobin can 
be detected, while at the endosomal pH 5.5 more than 90% of the erythrocytes got 
lysed by the peptide. The lytic behaviour of Inf7-siRNA is comparable. While there is 
no lytic activity at pH 7.4 and an intermediate cell lysis at pH 6.5 (17%) the peptide-
siRNA hybrid lyses 85% of the erythrocytes at pH 5.5.  
This data demonstrates that the covalent attachment of siRNA to the influenza peptide 
does neither influence its lytic activity nor its pH specificity. 
 
 
3.1.2.2 Influence of the covalent attachment of the influenza peptide on the 
activity of siRNA 
 
The influence of the attachment of macromolecules to one or several ends of the 
siRNA strands on its knockdown efficiency has been investigated intensively.142 
However results are contradictory. In summary one can say, that it strongly depends 
on the position and type of attachment as well as on the properties of the attached 
macromolecule, if and how much the siRNAs silencing activity is reduced. Designing 
the described system, it was decided to attach the peptide at the 5’-end of its sense 
strand via a disulfide linkage to avoid any influence of the attached peptide on the 
silencing ability. To explore the specific knockdown efficiency and toxicity of the 
peptide-siRNA conjugate, transfection experiments with defined cationic polymers, 
known to work very good for siRNA delivery were performed (46, 49 for structure see 
Materials and Methods section), comparing peptide conjugated siRNA with 
unconjugated siRNA (Fig. 3.6).  
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Fig. 3.6 Target gene silencing and toxicity of the Inf7-siRNA hybrid compared to free siRNA. 
Neuro2A cells stably expressing eGFP-Luciferase were transfected either with 400 nM unmodified 
siRNA (black bars) or 400 nM Inf7-siRNA hybrid (white bars). For transfection, polycation 46 and 49 
were used at indicated N/P ratios (1-6). A: Determination of luciferase-activity; B: Determination of cell 
viability via MTT assay. Results are presented as relative values compared to HBG treated cells. 
 
Transfecting Neuro2A cells with unmodified siRNA (siGFP) using polycation 46 and 49 
led to a significant reporter gene knockdown at N/P ratios 3 and 6, while at N/P 1 the 
expression of the eGFP-Luciferase fusion protein remains unmodified. Regarding cell 
viability, no significant decrease could be observed. The use of peptide modified 
siRNA (Inf7-siGFP) led to comparable knockdown results for both polymers at N/P 3 
and 6. At N/P 1 the silencing efficiency is even raised compared to unmodified siRNA. 
In both cases a knockdown to 40-50% of expression could be observed. In cell 
viability no significant differences were detectable (Fig. 3.6 B). 
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3.1.2.3 Influence of peptide conjugation on particle formation 
 
Particle formation and stability are two important criteria in the design of carrier 
systems. During in vitro siRNA delivery but more important during in vivo delivery, the 
formed particles have to be stable to protect the siRNA and deliver the cargo to its 
target cell. The ability to form particles as well as its stability is mainly influenced by 
electrostatic interactions of polyanion and polycation. Thus modifications of one of 
these structures could have impact on the particles. To study the influence of the 
peptide modification of siRNA, its interactions with polycation 49 has been evaluated 
in a gel shift assay (Fig. 3.7). 
 
 
Fig. 3.7 Gel shift assay comparison of polyplex formation ability using siRNA and Inf7-siRNA 
containing particles. Polycation: 49, 3-40: nitrogen to phosphate ratio for polyplex formation, C: 
control (siRNA without polymer). 
 
For unconjugated siRNA the gel shift assay reveals that interactions with the polymer 
already take place at the lowest N/P ratio. Although just little amounts of completely 
free siRNA can be observed, most of the material is just slightly hampered to migrate 
into the gel. At N/P 20 and higher the migration is completely stopped. Inf7-siRNA 
shows a slightly altered behaviour in this assay. At N/P 3 the migration of the siRNA 
construct is also just partly influenced. In comparison to unconjugated siRNA, the 
interaction with the polycation seems to be stronger, because the complete inhibition 
of movement is already reached at an N/P ratio of 12. 
The gel retardation assay just gives limited information of the interactions between 
both ionic components. It can just verify the impact of the polymer on the siRNA 
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migration. As a hampered migration can also result from strong aggregation, the 
particle size of polyplexes formed with modified and unmodified siRNA was compared 
by dynamic light scattering (DLS) to further explore the influence of the peptide 
(table 3.2). 
The size measurements clearly show that the conjugated as well as the unconjugated 
siRNA form small defined particles with a diameter of ~17 nm at an N/P of 12 or 
higher. Both structures led to strong aggregation at N/P 3, making a size 
measurement impossible. The only difference could be observed at N/P 6. Unmodified 
siRNA forms particles with a diameter of 321 nm, while Inf7-siRNA based polyplexes 
have a diameter of 140 nm. 
 
Table 3.2 Particle diameter of siRNA or Inf7-siRNA containing polyplexes measured by dynamic 
light scattering. N/P: nitrogen to phosphate ratio for polyplex formation, used polycation: 49. 
 
 
Summarizing these experiments, the particle formation of siRNA and polycation 49 is 
not negatively influenced by the attached peptide. Neither ionic interactions nor 
particle size is dramatically influenced by this structure. 
 
 
3.1.3 Silencing activity of the Inf7-siRNA hybrid in vitro 
 
The purpose of this system was to create siRNA that is independent of the 
endosomolytic activity of its carrier system. Thus the role of the delivery vehicle should 
be reduced to protection, particle formation and cell attachment followed by 
endocytosis. As it has been shown that the biological function of the siRNA as well as 
siRNA Inf7-siRNA
3 --- ---
6 321 (± 112) 140 (± 26)
12 16 (± 3) 16 (± 2)
20 14 (± 2) 15 (± 2)
40 8 (± 1) 12 (± 2)
Particle diameter [nm]
N/P
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of the peptide remains fully active, the modified siRNA was transfected with a defined 
polymer lacking efficient endosomal escape ability (76, Fig. 3.8). 
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Fig. 3.8 Comparison of luciferase expression after transfection with siRNA and Inf7-siRNA using 
a polymer with low endosomal escape ability. Neuro2A cells stably expressing eGFP-Luciferase 
were transfected either with 400 nM Inf7-siRNA (right bars) or 400 nM unmodified siRNA (left bars) 
using polycation 76. Luciferase expression was detected. The data is presented as relative values 
compared to HBG treated cells. The experiment was performed by Thomas Fröhlich as part of his PhD 
thesis (in preparation). 
 
Transfection of Neuro2A cells stably expressing eGFP-Luciferase with unmodified 
siRNA using polymer 76 led to a specific knockdown of 50% luciferase expression 
only at N/P ratios 6 and 12 compared to control siRNA. At N/P 1 and 3 no significant 
knockdown could be detected. Transfecting the cells with conjugated siRNA resulted 
in a target gene silencing to ~20% in all N/P ratios. In contrast, conjugated control 
siRNA showed no knockdown, indicating that the gene silencing is specific. 
Summarizing this chapter a defined pure hybrid of influenza peptide and siRNA was 
synthesized. The covalent attachment does neither influence the peptides lytic activity 
nor the siRNAs silencing ability. The combination of these two structures leads to a 
macromolecule that is able to overcome the limitation of endosomal escape 
independent of the endosome disruptive force of the polycationic carrier system. 
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3.2 Ligand mediated, targeted siRNA delivery 
 
Overcoming bottlenecks in delivery is the main challenge developing efficient siRNA 
carrier systems. Beside the endosomal escape (chapter 3.1), specific cell targeting is 
one of the major limitations in this field. In vitro in general just one cell population is 
existent in one experimental setting. Thus transfecting just a certain subpopulation is 
no topic in in vitro cell culture. The situation changes in vivo. Polyplexes should be 
able to reach the targeted cell population after systemic injection, avoiding interactions 
with or transfection of other cell populations. Thus they need to be shielded for all 
cells, having a certain “homing structure” that identifies the addressed tissue or cell 
population.  
In case of tumor homing, this can be done in two different ways: (i) accumulation of 
polyplexes by enhanced permeability and retention (EPR) effect or (ii) cell specific 
ligand based targeting. Both described in detail in chapter 1.4.2.3. Since the EPR 
effect is a more passive tissue targeting, the ligand based cell targeting is very 
specific. Special receptors are upregulated on certain cell populations while they are 
absent on other cells. These receptors can be addressed via the incorporation of a 
receptor ligand in the carrier system. If the receptor is internalized by endocytosis after 
ligand attachment, the whole polyplex enters the cell. In case of tumor targeting, 
significantly up regulated endocytosed receptors are the transferrin-, the epidermal 
growth factor- and the folic acid receptor (see chapter 1.4.2.3). 
Incorporation of one of these targeting ligands into the carrier system was in common 
concepts realized by covalent attachment of the ligand to the polycationic backbone 
(in case of polyplexes) or to lipid structures (in case of lipoplexes and liposomes). This 
kind of attachment to overcome the hurdle of cell attachment and endocytosis leads to 
a new crucial limitation, the polyplex stability. As the siRNA is incorporated stable into 
the polyplex, it has excess to the ligands homing activity. If the polyplex is not stable 
enough, the siRNA is lost, due to loss of targeting. Especially the process of cell 
attachment could lead to the release of siRNA out of the polyplex, due to the highly 
negative charged cell surface. 
Thus a more reasonable design of a carrier system would be the covalent attachment 
of a targeting ligand to the siRNA and its complexation with unmodified polycations. 
This strategy makes the tumor homing of the therapeutic siRNA independent of the 
stability of the polyplex although its protecting, stabilizing and endosomolytic effect 
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retains. In the following chapter, the design, synthesis, purification and biological 
evaluation of such a siRNA construct is described. 
 
 
3.2.1 Design and synthesis of the FolicAcid-PEG24-siRNA hybrid 
 
The basic idea of this concept is the synthesis of defined structures. Thus it was 
decided to synthesis the targeting structure by common solid phase supported peptide 
synthesis (SPPS). This strategy, first published by Merrifield et al.,137 enables the 
generation of highly defined macromolecules, using high excesses of educts during 
the reaction and easy removal of by-products by simple filtration processes.  
As the solid phase peptide synthesis is based on building amide-bonds to grow the 
structure, the choice of ligands was limited to structures containing such bonds. Thus 
beside of peptide ligands (e.g. B6 or GE11) derived from phage display, folic acid, 
composed of glutamic acid and pteroic acid connected via an amide bond, was a 
feasible ligand for this strategy. As folic acid is a ligand with a high binding affinity to 
its receptor (10-10 M),110 it was chosen for a first proof of concept. Being responsible 
for cell targeting, the ligand should be represented by the polyplex to enable receptor 
ligand interactions. Therefore a spacer to overcome the distance between 
incorporated siRNA and exposed ligand was needed. The use of commercially 
available α-amino-, ω-carboxy-PEG (Fmoc-N-amido-dPEG®24-acid, QuantaBiodesign, 
Powell, Ohio, USA) enabled the introduction of a defined polyethylene glycol spacer 
on solid phase (see Fig. 3.9). 
The covalent attachment of a targeting moiety should not influence the siRNAs 
silencing efficiency. Hence the ligand construct was attached by a disulfide bond at 
the 5’-end of its sense strand. As the disulfide bond is cleaved in the cytosol, the 
siRNA modification is minimal. Taking into account all these features, the synthesis 
was performed as shown in Fig. 3.9. 
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Fig. 3.9 Solid phase synthesis of FolA-PEG24-C. For synthesis, a 2-Chlorotrytyl chloride resin was 
chosen. After loading the resin with Cys(Trt)-NH2, further components were attached, using standard 
Fmoc based synthesis strategy. (i) Deprotection: 20% (v/v) piperidine in DMF, four times 10 min; 
(ii) Coupling: AA/PyBop/HOBt/DIPEA (4/4/4/8) in DMF/DCM, 60 min; (iii) tfa-removal: 1 M ammonium 
hydroxide/DMF (1/1, v/v), four times 30 min; (iv) Cleavage: TFA/TIS/H2O (95/2.5/2.5), 2 h. 
 
The ligand-spacer complex was generated by SPPS, starting with an Fmoc protected 
cysteine on solid support, containing a thiol group for the attachment to siRNA. After 
removing the protective group dPEG24, glutamic acid and N10-(trifluoroacetyl)pteroic 
acid were consecutively attached to the growing molecule, resulting in the in Fig. 3.9 
shown structure. After removing the trifluoroacetyl protection group with ammonium 
hydroxide, the peptidic structure was cleaved of the resin and purified by precipitation. 
The resulting peptide was analyzed by RP-HPLC (Fig. 3.10) and MALDI-TOF-MS 
(Fig. 3.11). 
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Fig. 3.10 Chromatogram of the analytical RP-HPLC of FolA-PEG24-C. After cleavage of the peptidic 
structure and purification by precipitation, the purity was checked by RP-HPLC using a sunfire C18 
column (Waters, Milford, MA). A gradient from 5-100% (v/v) acetonitrile in water (0.1% (v/v) TFA) was 
applied for 20 min. 
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Fig. 3.11 MALDI-TOF-MS spectrum of FolA-PEG24-C. After cleavage of the peptidic structure and 
purification by precipitation, the identity was checked by mass spectrometry. Calculated mass: 1673 Da 
Used matrix: 2,5-dihydroxybenzoic acid (DHB). 
 
The analysis proved purity as well as identity of the synthesized structure. This 
defined peptidic ligand was coupled in a second step to the backbone of the siRNA, as 
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summarized in Fig. 3.12. Same as for the attachment of the influenza peptide, a thiol 
modified siRNA, protected as disulfide was chosen for the synthesis. Thus it had to be 
deprotected by the treatment with TCEP, purified by ion exchange chromatography 
and activated using a high excess of DTNB. After renewed purification by ion 
exchange chromatography, the peptidic ligand structure was coupled via its free thiol 
group, building a disulfide bond with the siRNA. 
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Fig. 3.12 Synthesis of the FolA-PEG24-siRNA conjugate. After deprotection of the thiol group and 
purification by ion exchange chromatography, the thiol bearing siRNA was activated with DTNB. 
Additional purification of the product allowed the defined attachment of the cysteine containing 
pegylated ligand via a disulfide bridge. TCEP: (2-carboxyethyl)phosphine, DTNB: 5,5'-dithiobis-(2-
nitrobenzoic acid). 
 
The resulting targeted siRNA was purified by ion exchange chromatography 
(Fig. 3.13). To identify the product, fractions showing absorption at 260 nm were 
collected and analyzed by agarose gel electrophoresis (Fig. 3.14). 
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Fig. 3.13 Chromatogram of the ion exchange chromatographic purification of the FolA-PEG24-
siRNA hybrid. After loading the sample onto a ResourceQ column using 20 mM Hepes, pH 6.5, 50 mM 
NaCl, 30% acetonitrile and a washing step using same buffer with 200 mM NaCl, the elution of the 
product was performed applying a gradient of 10 mM NaCl/min and a flow of 1 mL/min over 30 min. 1-
20: collected fractions. Detection wavelength: 260 nm. 
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Fig. 3.14 Agarose gel analysis of the ion exchange chromatographic purification. Fractions, 
collected during ion exchange chromatographic purification of FolA-PEG24-siRNA were analyzed in a 
2.5% agarose gel. 100 V were applied for 100 min. C: control (unmodified siRNA), 1-20: Fractions 
collected during purification. 
 
As shown in Fig. 3.13 the targeted siRNA binds to the column, when a buffer 
containing 20 mM Hepes, pH 6.5 and 50 mM NaCl, 30% acetonitrile was used. During 
the sodium chloride gradient (10 mM/min, 1 mL/min) fractions showing absorption at 
260 nm elute. The analytical gel electrophoresis reveals that these fractions contain 
siRNA. Two populations can be distinguished. One contained siRNA that migrates as 
far as free control siRNA in the gel, the other population containing retarded siRNA. 
Fractions containing retarded siRNA were pooled and used for further analysis. 
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3.2.2 In vitro gene silencing using FolA-PEG24-siRNA 
 
It was hypothesized that the conjugate is not able to act as functional carrier itself, due 
to the absence of an endosomolytic function. The combination of the targeted siRNA 
with an endosomolytic active polymer should result in an efficient reporter gene 
knockdown. In an experimental setting, folic acid receptor positive KB cells stably 
expressing the eGFP-Luciferase gene were transfected with polyplexes containing 
different amounts of targeted siRNA and a defined polycation 229 (Fig. 3.15). 
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Fig. 3.15 In vitro target gene silencing using targeted siRNA. Folic acid receptor positive KB cells 
stably expressing eGFP-Luc were transfected with 400 nM siRNA polyplexes formed with polymer 229 
Indicated numbers represent the molar percentage of siRNA molecules replaced by FolA-PEG24-siRNA. 
Targeted siRNA without polymer was used for transfection as control. Used nitrogen to phosphate (N/P) 
ratio: 12. 
 
As already expected, the FolA-PEG24-siRNA conjugate does not lead to a knockdown. 
Incubating the cells with polyplexes without targeted siRNA for 30 min does also not 
result in gene silencing. The addition of different amounts of targeted siRNA led at 
ratios above 25% to an efficient specific gene silencing to ~35% of expression. Using 
folic acid targeted siRNA leads to increased levels of luciferase expression without 
polymers and with 10% and 25% mixtures, while showing a slight toxicity at higher 
ratios. 
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3.2.3 Modified synthesis of targeted siRNA 
 
As the proof of concept revealed, that the covalent attachment of a targeting ligand to 
siRNA resulted in a functional construct, the design was further improved. The used 
synthesis was laborious, time consuming and cost intensive due to three synthesis 
and purification steps (Fig. 3.12). To overcome these problems, a new reaction type, 
the Huisgen cycloaddition (1,3-dipolar cycloaddition) was chosen. Known to be very 
efficient and specific, this was a promising candidate for the synthesis of targeted 
siRNA. To enable the attachment of the ligand structure to the siRNAs alkyne the solid 
phase protocol to generate targeted structures (Fig. 3.9) was slightly modified. Instead 
of a resin bound Cys(Trt)-Fmoc, the synthesis was started with (S)-5-azido-2-(Fmoc-
amino)pentanoic acid on solid support, resulting in the peptidic structure FolA-PEG24-
azide as shown in Fig. 3.16. To maintain the advantage of a biodegradable disulfide 
linkage the siRNA was modified with a disulfide bond between backbone and alkyne 
group (see Fig. 3.17). 
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Fig. 3.16 Solid phase synthesis of FolA-PEG24-Azide. For synthesis, a 2-Chlorotrytyl chloride resin 
was chosen. After loading the resin with (S)-5-2-(Fmoc-amino)pentanoic acid, further components were 
attached, using standard Fmoc based synthesis strategy. (i) Deprotection: 20% (v/v) piperidine in DMF, 
four times 10 min; (ii) Coupling: AA/PyBop/HOBt/DIPEA (4/4/4/8) in DMF/DCM, 60 min; (iii) tfa-removal: 
1 M ammonium hydroxide/DMF (1/1, v/v), four times 30 min; (iv) Cleavage: TFA/TIS/H2O (95/2.5/2.5), 
1 h. 
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Using Cu(I) as catalyst the synthesis could be reduced to one reaction and one 
purification step (Fig. 3.17). The resulting product is termed FolA-PEG24-click-siRNA in 
the following text. After purification via ion exchange chromatography and 
determination of fractions containing modified siRNA, the product was checked for 
identity by MALDI-TOF-MS analysis (Fig. 3.18). 
 
Fig. 3.17 One step synthesis of FolA-PEG24-click-siRNA. The targeting domain was coupled to the 
siRNA by Cu(I) catalyzed 1,3-dipolar cycloaddition. (i): TBTA/CuBr solution (0.1 M TBTA/0.1 M CuBr 
2/1 (v/v) each in DMSO/tertiary Butanol 3/1 (v/v)), 2 h, 37°C, constant shaking. 
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Fig. 3.18 MALDI-TOF-MS spectrum of FolA-PEG24-click-siCtrl. After purification via ion exchange 
chromatography and analysis with agarose gel electrophoresis, the FolA-PEG24-click-siRNA was 
identified by mass spectrometry. m/z 6724: antisense strand (Calculated mass: 6721 Da), m/z: 9007: 
modified sense strand (Calculated mass: 9004 Da). Used matrix: 3-hydroxypicolinic acid (HPA). 
 
As demonstrated by mass analysis, the product is composed of pure modified siRNA. 
The two peak populations in Fig. 3.18 display the unmodified antisense strand (m/z 
6724) and the modified sense strand (m/z 9007). Additional peaks result from salt 
adducts of the pure product. 
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3.2.4 Functional evaluation of FolA-PEG24-click-siRNA 
 
As the modification of siRNA as well as folic acid can have a strong influence on its 
activity, the biological behaviour of the modified structure had to be shown, using the 
same assays. 
 
 
3.2.4.1 Influence of the covalent siRNA attachment on the receptor binding 
ability of folic acid 
 
The binding ability of siRNA bound folic acid was checked qualitatively by 
fluorescence microscopy (Fig. 3.19) and quantitatively by flow cytometry (Fig. 3.20). 
For that purpose the siRNA used in the synthesis was modified by a Cy5 label at the 
5’-end of its antisense strand. As control sequence, nontargeted siRNA 
(PEG24-click-siRNA-Cy5) was chosen. 
 
 
Fig. 3.19 Fluorescence microscopic pictures of the ligand mediated uptake of FolA-PEG24-click-
siRNA. KB cells expressing the folic acid receptor were incubated for 30 min with A: Cy5 labeled FolA-
PEG24-click-siRNA or C: labeled PEG24-click-siRNA. To prove the specificity of uptake KB cells were B: 
preincubated with free folic acid for competitive inhibition or D: folic acid receptor negative Neuro2A 
cells were used. The experiment was performed by Thomas Fröhlich as part of his PhD thesis (in 
preparation). 
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Fig. 3.20 Flow cytometric analysis for cell association of FolA-PEG24-click-siRNA. A: Folic acid 
receptor positive KB cells were treated with Cy5 labeled FolA-PEG24-click-siRNA or its analogues for 
30 min. After washing, Cy5 positive cells were detected by flow cytometry. I: untransfected cells, II: 
FolA-PEG24-click-siRNA with folic acid competition, III: PEG24-click-siRNA, IV: FolA-PEG24-click-siRNA; 
B: Folic acid receptor negative Neuro2A cells: I: untransfected cells, II: FolA-PEG24-click-siRNA. The 
experiment was performed by Thomas Fröhlich as part of his PhD thesis (in preparation). 
 
Regarding the results of the fluorescence microscopy, the labeled 
FolA-PEG24-click-siRNA was efficiently taken up by KB cells (Fig. 3.19A), known for 
strong expression of the folic acid receptor. Nontargeted siRNA (Fig. 3.19C) showed 
no uptake, as does the targeted siRNA, when cells were preincubated with free folic 
acid before treatment (Fig. 3.19B). Folic acid receptor negative control cells did also 
not show a significant internalization of the conjugate (Fig. 3.19D). These qualitative 
results could be supported by flow cytometry. The treatment of KB cells with labelled 
FolA-PEG24-click-siRNA led to a significant shift of the fluorescent signal in the whole 
cell population (Fig. 3.20A IV), while all controls did not lead to a significant shift. 
 
 
3.2.4.2 Influence of covalent attachment of FolA-PEG24 on the activity of 
siRNA 
 
Although the modification of folic acid with a PEG-spacer and an attached siRNA did 
not alter its specificity and affinity to its receptor, the transfection of cells with FolA-
                           KB                                                                        Neuro2A 
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PEG24-siRNA did not lead to a significant reporter gene silencing. To exclude, that the 
conjugate as well as the type of reaction interferes with the silencing ability of the 
siRNA, the different constructs were transfected in a receptor independent setting to 
compare the influence of the modification on the silencing efficiency. As shown in 
Fig. 3.21 Neuro2A cells, with a low folic acid receptor level were transfected using a 
functional polycation (230). 
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Fig. 3.21 Gene silencing activity of conjugated siRNA in comparison to unconjugated siRNA. 
Neuro2A cells stably expressing eGFP-Luciferase were transfected using the different siRNA 
conjugates in combination with polycation 230 at indicated N/P ratios of 12 or 20. The experiment was 
performed by Thomas Fröhlich as part of his PhD thesis (in preparation). 
 
The knockdown efficiency of both siRNA conjugates is around 20% of the expression 
level of untreated cells and thus similar to that of unconjugated siRNA. As the controls 
of all three types of siRNA have a similar expression level the modifications show to 
have neither an influence on the silencing efficiency nor on specificity and toxicity.  
 
 
3.2.5 Incorporation of FolA-PEG24-click-siRNA into an efficient and functional 
carrier system 
 
Free FolA-PEG24-click-siRNA has shown to be not able to regulate the expression 
level of the target protein and thus is not able to silence a gene, although it is taken up 
very efficiently by specific interactions with the folic acid receptor and bears a 
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completely functional siRNA. Thus it was hypothesized that during intracellular 
delivery the endosomal escape is the crucial bottleneck of this conjugate. To develop 
a functional carrier system, the ligand PEG conjugated siRNA was combined with a 
simple, defined polycation known to force the proton sponge effect as an efficient 
endosomal escape mechanism. The used polycation, synthesized by solid phase 
supported peptide synthesis consists of three arms, each build of three Stp units 
terminated by a cysteine (386, for structure see Materials and Methods). In 
combination with the siRNA conjugate it should form stable polyplexes, present the 
pegylated ligand on its surface and lead to an efficient delivery system by combination 
of receptor mediated uptake and efficient endosomal escape. 
 
 
3.2.5.1 Physicochemical characterization of FolA-PEG24-click-siRNA 
 
To prove that this combination can result in an efficient delivery system, the ability to 
build polyplexes was tested in a gel migration assay and compared to free siRNA. The 
resulting gel picture is shown in Fig. 3.22. It shows siRNA, PEG24-click-siRNA and 
FolA-PEG24-click-siRNA after complex formation with polymer 386 at two different N/P 
ratios. 
C         1         2        3         1        2         3 
N/P 6 N/P 12
 
Fig. 3.22 Comparison of polyplex stability by agarose gel shift assay. Polyplex formation of 
unconjugated siRNA (1) FolA-PEG24-click-siRNA (2) or PEG24-click-siRNA (3) in combination with 
polycation 386 was tested at indicated N/P ratios. C: control, free siRNA. The experiment was 
performed by Thomas Fröhlich as part of his PhD thesis (in preparation). 
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In contrast to free siRNA (C: control), the bands for all polyplexes are strongly 
reduced. In all pockets non migrating siRNA can be detected. Thus conjugated siRNA 
still retains its ability to interact with the polycationic carrier. Comparing conjugated 
(2, 3) to unconjugated siRNA, slight differences can be observed. In case of PEG24-
click-siRNA and FolA-PEG24-click-siRNA a small percentage of nucleic acids is able to 
migrate into the gel, while for unconjugated siRNA, no free nucleic acids can be 
detected, indicating a slight destabilization of polyplexes by PEG modification of 
siRNA. To further characterize the particle formation of conjugated and unconjugated 
siRNA, particle size and zeta potential of these structures was determined (table 3.3). 
 
Table 3.3 Size and zeta potential of polyplexes of different siRNA conjugates in combination 
with polycation 386. 
 
 
At both N/P ratios the polyplexes formed with unconjugated siRNA had a particle size 
around 600 nm and a zeta potential of 20 mV. In contrast particles formed with 
conjugated siRNA have a diameter between 933 nm – 1075 nm. The zeta potential of 
particles formed with siRNA conjugates is strongly reduced. At N/P 6 down to 11.0 – 
13.8 mV (31-45% reduction) and at N/P 12 13.3 – 15.6 mV (25-36% reduction). These 
results show that interactions take place between polymer 386 and the different siRNA 
conjugates leading to stable particles. Although these particles are slightly bigger 
compared to particles formed with unconjugated siRNA, the pegylation significantly 
reduces the zeta potential. 
The strong reduction of the zeta potential indicated, that PEG molecules and thus the 
targeting structures are presented on the polyplex surface. Thus a receptor specific 
uptake of particles should be enabled. To prove this, KB cells expressing the folic acid 
N/P Polyplex Diameter [nm] Zeta potential [mV]
siRNA 633 (±44) 20.1 (±1.0)
FolA-PEG24-click-siRNA 933 (±50) 11.0 (±0.6)
PEG24-click-siRNA 1075 (±64) 13.8 (±0.4)
siRNA 597 (±32) 20.8 (±1.3)
FolA-PEG24-click-siRNA 953 (±145) 13.3 (±0.2)
PEG24-click-siRNA 1035 (±147) 15.6 (±0.5)
6/1
12/1
Results 
68 
receptor were transfected with the labeled FolA-PEG24-click-siRNA or its nontargeted 
analogue. Particle uptake was subsequently explored by flow cytometry. As the 
resulting data (Fig 3.23) demonstrate, cells transfected with particles consisting of 
nontargeted siRNA and polymer 386 show a slight positive Cy5 signal, indicating a 
weak polyplex association at N/P 6. Polyplexes carrying pegylated siRNA lead to an 
increased signal intensity. In contrast the introduction of folic acid into the structure 
leads to an 10- to 40-fold increase in cellular uptake at N/P 6 compared to pegylated 
siRNA or unconjugated siRNA. At N/P 12 the cell association is increased for all 
polyplex variants compared to N/P 6. As unconjugated and pegylated siRNA result in 
the same transfection efficiency folic acid targeted siRNA still leads to an 10-fold 
increased uptake of polyplexes. 
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Fig. 3.23 Flow cytometric analysis for cell association of FolA-PEG24-click-siRNA in combination 
with polycation 386. I: PEG24-click-siRNA, II: FolA-PEG24-click-siRNA with folic acid competition, III: 
FolA-PEG24-click-siRNA. The experiment was performed by Thomas Fröhlich as part of his PhD thesis 
(in preparation). 
 
 
3.2.5.2 FolA-PEG24-click-siRNA in combination with polymer 386 for 
efficient gene silencing 
 
In the last sections the functionality of the FolA-PEG24-click-siRNA construct as well 
as its inefficiency in endosomal escape has been shown in detail. To overcome the 
limitation in intracellular delivery the conjugate was combined with the defined 
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polycation 386 that is able to escape out of the endosome due to the proton sponge 
ability of its Stp units.80 These both molecules showed to be able to build stable 
particles with strongly reduced zeta potential due to the PEG shielding, compared to 
particles formed with unconjugated siRNA. Thus this combination of macromolecules 
shows to have the potential to act as efficient carrier system. To prove this, these 
polyplexes were used in an in vitro experimental setting to down regulate the eGFP-
Luciferase fusion gene in KB cells expressing the folic acid receptor (Fig. 3.24). 
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Fig. 3.24 Reporter gene silencing of targeted and nontargeted pegylated siRNA in combination 
with polycation 386. KB cells stably expressing eGFP-Luciferase were transfected either with 400 nM 
FolA-PEG24 modified siRNA (left bars) or 400 nM PEG24-click-siRNA (right bars). For transfection 
polycation 386 was used at N/P 6 (A) or N/P 12 (B). The experiment was performed by Thomas 
Fröhlich as part of his PhD thesis (in preparation). 
 
The transfection results reveal that the carrier system is able to silence the target gene 
in a receptor specific manner. Using 100% nontargeted siRNA for polyplex formation 
(0% FolA-PEG24-click-siRNA) resulted in the absence of gene silencing, while all 
polyplexes consisting either of a mixture of ligand conjugated and unconjugated 
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siRNA or pure ligand conjugated siRNA resulted in significant gene silencing down to 
25% (for N/P 6) or 7% (for N/P 12) of the expression level of control cells. In contrast 
the use of pegylated siRNA did not lead to an effect on the target cells at N/P 6 and 
just to a slight regulation (~25% reduction) at N/P 12. The use of control siRNA 
resulted in full expression levels at any N/P ratio. 
 
In conclusion, it could be demonstrated, that the synthesis of a defined FolA-PEG-
siRNA molecule is possible. Its identity and functionality could be proven in different 
assays, showing no significant differences between the two different synthesis 
strategies. As this molecule does not contain any functional group for endosomal 
escape, it does not lead to gene silencing when used as transfection agent. The 
combination with a defined carrier system, forcing endosomal escape, resulted in very 
efficient and specific reporter gene knockdown. Thus the presented structure reduces 
the role of the polymer to endosomal escape and particle formation and thus 
increases its design space. 
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3.3 Targeted polycation for cell specific siRNA delivery in vitro and in vivo 
 
Targeting the cell of interest remains one of the major bottlenecks of todays RNAi 
technology. Reaching a specific cell population does in case of polyplex mediated 
delivery not only imply the enhancement of affinity to this special cell type, but also to 
avoid attachment processes to nontargeted cells. Thus, the common interpretation of 
Paul Ehrlichs “magic bullet” in case of polyplex mediated siRNA delivery is a 
polycation based particle incorporating the nucleic acid, which should be completely 
shielded by e.g. a surrounding layer of polyethylene glycol to avoid any unspecific cell 
attachment and an outer layer of ligands to enable interactions with the target cell. 
This idea was up to now limited by very unspecific synthesis strategies. Conjugation of 
polyethylene glycol (PEG) or pegylated targeting ligands was performed by random 
attachment to reactive groups of the polymeric backbone in most cases. The 
pegylation does not only shield the polymer of interaction with cells but also of its 
interaction with the nucleic acid. Thus the addition of high amounts of PEG to shield 
the particle could lead to a loss of particle formation ability. A solution for this problem 
was found by post-pegylation.143 In this strategy the polyplex was formed prior to 
pegylation. Regarding reproducibility and analysis of the product, this method is 
inefficient for the production of defined structures. A more reasonable approach to 
separate the functionalities of shielding and nucleic acid binding ability is the synthesis 
of block copolymers.144 These structures, consisting of two different subunits, one 
polycationic region for nucleic acid binding, attached to a second subunit consisting of 
one or several PEG molecules enable a maximum shielding capacity of the polyplex, 
maintaining a good nucleic acid binding ability. Until now these structures still lack 
definition due to substructures with a high polydispersity. This chapter deals with the 
synthesis, purification and biological evaluation of a peptide based, highly defined 
structure composed of a polycationic backbone and a defined PEG bearing folic acid 
as targeting ligand. 
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3.3.1 Design and synthesis of a structural defined targeted polycation 
 
A highly defined structure for ligand based delivery of siRNA to target cells was the 
idea of this strategy. As solid phase peptide synthesis was already found out to be an 
excellent tool for the synthesis of defined polymers,140 this method was chosen to 
generate this structure. The requirements of the planed structure were: 
 
- ability to build stable complexes with nucleic acids, especially siRNA 
- having a reasonable shielding via a PEG chain at a defined position 
- containing an efficient targeting ligand  
 
To enable the complexation of the carrier with siRNA, its synthesis was based on a 
linear backbone consisting of polyamino amides using Stp (16-Amino-4-oxo-5,8,11,14-
tetraaza-hexadecanoic acid) as building block (previously described by Schaffert et 
al.140). Improved polyplex stability should be reached by the incorporation of cysteines 
at both ends of the cationic backbone. To enable the defined attachment of PEG, a 
branching lysine was inserted in the middle of the polycation. For highest definition a 
commercially available, monodisperse, α-amino, ω-carboxy PEG24 was chosen with 
folic acid as high affinity ligand. Synthesis and resulting structure is shown in Fig. 3.25. 
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Fig. 3.25 Design and synthesis of FolA-PEG24-K(Stp4-C)2. Stp: 16-Amino-4-oxo-5,8,11,14-tetraaza-
hexadecanoic acid, dPEG24: defined poly(ethylene glycol) consisting of 24 monomers, trt: trityl 
protection group, tBu: tert butyl protection group, boc: tert butyl protection group, tfa: trifluoroacetic acid 
protection group. (i) Deprotection: 20% (v/v) piperidine in DMF, four times 10 min; (ii) Coupling: 
AA/PyBop/HOBt/DIPEA (4/4/4/8) in DMF/DCM, 60 min; (iii) deprotection: 1 M ammonium 
hydroxide/DMF (1/1, v/v), four times 30 min; (iv) cleavage: TFA/TIS/H2O (95/2.5/2.5), 2 h. 
 
For further experiments, analogues lacking targeting or crosslinking ability were 
synthesized. For purification the peptidic structures were precipitated and lyophilized 
after cleavage from the resin and evaporation of solvents. Purity and identity were 
Results 
74 
shown by RP-HPLC (Fig. 3.26), MALDI-TOF-MS (Fig. 3.27) analysis and 1H-NMR 
(see appendix). 
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Fig. 3.26 Chromatogram of the analytical RP-HPLC of FolA-PEG24-K(Stp4-C)2. After cleavage of the 
product from the resin and precipitation the purity of the peptidic structure was analyzed by RP-HPLC 
using a sunfire C18 column (waters). A gradient from 5-100% (v/v) acetonitrile in water (0.1% (v/v) TFA) 
was applied in 20 min. 
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Fig. 3.27 MALDI-TOF-MS spectrum of FolA-PEG24-K(Stp4-C)2. After cleavage of the peptidic 
structure and purification by precipitation, the identity was checked by mass spectrometry (Calculated 
mass: 4076 Da). The analysis was performed by our collaborators at the Roche Kulmbach GmbH. 
Used matrix: 2,5-dihydroxybencoic acid (DHB). 
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The analysis reveals purity above 90% and a single mass peak at the estimated 
position. Same results could be found for both synthesized analogues as shown in 
table 3.3 (see appendix for detailed information). 
 
Table 3.4 Solid phase peptide synthesis based polycationic structures. Sequences are written 
from C- to N-terminus as synthesized on solid support. 
40434043C178H342N52O52S-Stp4-K(Stp4-S)-PEG24-FolA
40774076C178H342N52O50S2C-Stp4-K(Stp4-C)-PEG24-FolA
37203723C162H330N46O46S2A-PEG24-K(Stp4-C)2
Detected mass
[M+H]+
Calculated mass
[M+H]+FormulaSequence
 
 
 
3.3.2 Showing targeting by DNA delivery - A proof of concept 
 
First knockdown experiments using the targeted polycationic structure in combination 
with siRNA resulted in absence of silencing efficiency (data not shown). As this 
delivery system is very complex, having several substructures with different 
functionality, it was decided to show the proof of concept by DNA delivery. DNA 
delivery has certain parallels in comparison to siRNA delivery. Although complexation, 
stability, cell attachment, endocytosis and endosomal escape are not the same, they 
are in certain issues comparable. For this reason DNA delivery is a feasible model to 
show the efficiency and functionality of a delivery vehicle. Detection of 1% cells 
showing expression of a transgene is more sensitive than detecting the silencing of a 
gene by 1%. Thus this model gives a hint whether the system is able to work under 
certain conditions or whether it is completely inefficient. 
As model KB cells, known for high expression of the folate receptor were chosen. First 
transfection experiments revealed no transgene expression for the targeted as well as 
for the nontargeted structure (Fig. 3.28A), indicating that the carrier did not work. 
Addition of chloroquine 1 h after transfection resulted in transgene expressions shown 
in Fig. 3.28B. Toxicity studies did not show differences between targeted and 
nontargeted structures (Fig 3.28C,D). 
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Fig. 3.28 DNA delivery using defined folic acid targeted poly amines. Folic acid receptor positive 
KB cells were transfected with pDNA encoding for the eGFP-Luciferase fusion protein. A/B: luciferase 
gene expression 24h after transfection. C/D: Relative cell viability, compared to HBG treated cells. 
 
Using chloroquine after transfection, results in expression levels up to 106 relative light 
units per 10.000 cells. Chloroquine is known to enhance the endosomal escape. Thus 
this experiment shows that the system is lacking endosomal escape ability. Beside 
this, results show, that targeting and shielding are very efficient, because the uptake of 
polyplexes resulting in transgene expression can just be shown with the ligand 
containing polymer. 
 
As the endosomal escape is the crucial bottleneck using this delivery vehicle, it was 
decided to combine this carrier-system with the in chapter 3.1 described 
endosomolytic peptide-siRNA hybrid. 
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3.3.3 Functional evaluation of FolA-PEG24-K(Stp4-C)2 in combination with Inf7-
siRNA 
 
The designed carrier system shows a high complexity, consisting of different 
substructures with specific functionality. Although the combination was expected to 
have synergistic effects, nonfunctionality of one part could lead to an overall inefficient 
system, as already shown for endosomal escape. Hence the functionality and 
necessity of every single compound had to be tested in detail. 
 
 
3.3.3.1 Stabilization by disulfide bond formation 
 
As already described in the work of Schaffert et al.,80 short Stp units are not able to 
bind nucleic acids efficient enough to be stable during the delivery process. Thus 
stabilizing moieties have to be incorporated to enhance polyplex stability. In the 
described system, cysteines were introduced to enable disulfide bond formation 
among the oligo-Stp chains after polyplex formation and thus raise its stability. To 
prove the effect of the used mechanism, the functional carrier was compared with a 
carrier bearing serines instead of cysteines. Polyplexes were formed and loaded on an 
agarose gel to test their stability (Fig. 3.29). 
 
3        6       12      20      40       C               3        6        12       20      40       C
FolA-PEG24-K(Stp4-S)2FolA-PEG24-K(Stp4-C)2
 
Fig. 3.29 Comparison of polyplex stability by agarose gel shift assay. FolA-PEG24-K(Stp4-C)2 was 
compared with a structural analogue containing serine instead of cysteine. 3-40: nitrogen to phosphate 
(N/P) ratio for polyplex formation, C: control (free siRNA). 
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The analysis of the gel reveals that polyplexes formed with the functional polymer, are 
able to interact with the nucleic acid, hampering its migration in the gel at a nitrogen to 
phosphate (N/P) ratio of 6 or higher. The mutant lacking cysteines shows a 
significantly reduced interaction with siRNA. Just a slight ability to hamper the siRNA 
migration can be observed. This demonstrates that the construct is able to interact 
with the nucleic acid. To further identify the kind of interaction and to distinguish 
between particle formation and aggregation, particle size measurements via 
fluorescence correlation spectroscopy (FCS) were performed. Results are shown in 
table 3.5 and 3.6. 
 
Table 3.5 Particle size of polyplexes of FolA-PEG24-K(Stp4-C)2 and Inf7-siRNA. Particles have been 
formed in HBS buffer. rh: hydrodynamic radius. 
 
 
Table 3.6 Influence of buffer compounds and polymer targeting on particle size. Particles have 
been formed at an N/P ratio of 16. rh: hydrodynamic radius. 
 
 
Particle measurements reveal that the gel retardation of siRNA is not due to 
aggregation but due to the formation of particles between polycation and siRNA. The 
polyplexes have a hydrodynamic radius between 2.7 and 3.0 nm. Compared with free 
siRNA (2.1 nm) these particles are very small, composed of one siRNA surrounded by 
Conjugate buffer rh [nm]
FolA-PEG24-K(Stp4-C)2 HEPES 3.0 (± 0.1)
FolA-PEG24-K(Stp4-C)2 HBS 3.0 (± 0.1)
A-PEG24-K(Stp4-C)2 HBS 2.9 (± 0.1)
N/P rh [nm]
0 (siRNA) 2.1 (±0.1)
3 2.7 (±0.1)
6 2.9 (±0.1)
12 3.0 (±0.1)
16 3.0 (±0.1)
20 2.8 (±0.1)
40 2.8 (±0.1)
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a thin polymer layer (see table 3.5). Polyplex size is neither significantly influenced by 
the used mixing buffer nor by type of targeting (table 3.6). 
 
 
3.3.3.2 Pegylation for polyplex shielding 
 
Pegylation is a very important tool in case of targeted delivery. Besides targeting of a 
certain cell, shielding the polyplex from interactions with other cells is very important to 
get the vehicle to its target cell. Polyethylene glycol (PEG) has shown its shielding 
ability in many different studies. As it is non-toxic and highly soluble in water, it is ideal 
for use in a carrier system. In the described molecule a defined PEG, consisting of 
exactly 24 ethylene glycol subunits was used. To prove the shielding ability of this 
PEG chain, the zeta potential of particles formed under common conditions, was 
measured. As control the same structure lacking the PEG chain was used (table 3.7). 
 
Table 3.7 Zeta potential of pegylated and nonpegylated polyplexes. N/P: nitrogen to phosphate 
ratio for polyplex formation, n.d.: no zeta potential measurable 
 
 
The measurement data show that the zeta potential of nonpegylated particles is 
around 9-15 mV. In comparison the zeta potential of pegylated particles is completely 
neutral at all N/P ratios. As the difference of the carrier systems is just the PEG chain, 
this indicates that the degree of pegylation is enough to shield the particle completely.  
 
 
 
N/P A-PEG24-K(Stp4-C)2 A-K(Stp4-C)2
3 0.0 (±1.6) 9.3 (±1.8)
6 0.0 (±1.7) 12.7 (±1.9)
12 0.0 (±2.4) 14.2 (±1.7)
20 0.0 (±2.4) 12.9 (±1.9)
40 0.1 (±2.7) n.d.
Zetapotential [mV]
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3.3.3.3 Ligand incorporation for cell specific delivery of siRNA 
 
As it has been shown, that FolA-PEG24-K(Stp4-C)2 is able to bind siRNA efficiently, 
shielding its positive charge completely, a targeting ligand for specific cell attachment 
and uptake becomes very important. In this case folic acid was chosen, because it is 
described to have an extremely high affinity for its receptor. To test the functionality of 
the ligand, cell uptake was analyzed qualitatively by fluorescence microscopy 
(Fig. 3.30) and quantitatively by flow cytometry on KB cells expressing the folate 
receptor (Fig. 3.31).  
 
 
Fig. 3.30 Fluorescence microscopic pictures of the internalization of FolA-PEG24-K(Stp4-C)2 
polyplexes. A-D: overlay of DAPI and Cy5 channel; E-H: overlay of DAPI, Cy5 and transmission 
channel. A,E: KB cell transfected with FolA-PEG24-K(Stp4-C)2; B,F: KB cell transfected with FolA-
PEG24-K(Stp4-S)2, C,G: KB cells transfected with A- PEG24-K(Stp4-C)2; D,H: Neuro2A cells transfected 
with FolA-PEG24-K(Stp4-C)2. For all transfection Inf7-siAHA1-Cy5 was used. The experiment was 
performed by Thomas Fröhlich as part of his PhD thesis (in preparation). 
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Fig. 3.31 Flow cytometric analysis of receptor mediated cell uptake of FolA-PEG24-K(Stp4-C)2 
polyplexes. A: KB cell were transfected using functional FolA-PEG24-K(Stp4-C)2 (black line), non-
functional A-PEG24-K(Stp4-C)2 (dashed line) or non-functional FolA-PEG24-K(Stp4-S)2 (light grey line). 
Untransfected cells: dark grey line. B: Folic acid receptor negative Neuro2A cells were transfected 
using functional FolA-PEG24-K(Stp4-C)2 (dark line). Control cells: light grey line. C: cell association 
assay on ice. KB cells were incubated on ice with FolA-PEG24-K(Stp4-C)2 without (dashed line) and with 
(grey line) preincubation with free folic acid. Untransfected control cells: black line. The experiment was 
performed by Thomas Fröhlich as part of his PhD thesis (in preparation). 
 
The resulting histogram (Fig. 3.31) shows that polyplexes formed with folic acid 
targeted polymers were taken up very efficiently, indicated by the strong shift of the 
graph (Fig. 3.31A). In comparison polyplexes carrying just a PEG chain without ligand 
do not enter the cell. The uptake of folate receptor targeted polyplexes is strongly 
reduced on a folate receptor negative Neuro2A cell line (Fig. 3.31B) and can be 
inhibited by preincubation with free folic acid (Fig. 3.31C). Results were supported by 
microscopic pictures (Fig. 3.30). Summarizing, these results prove that the uptake of 
these particles is only receptor mediated lacking unwanted unspecific cell attachment. 
 
 
3.3.4 Specific in vitro gene silencing activity of FolA-PEG24-K(Stp4-C)2 in 
combination with endosomolytic active siRNA 
 
In the last chapter the functionality of every single substructure of the carrier system 
has been shown. Although the carrier works as expected, the system does not lead to 
an efficient knockdown when complexed with siRNA (data not shown). Initial 
experiments on DNA delivery revealed, that the carrier system shows no endosomal 
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escape ability. Thus it was decided to combine this defined and efficient carrier system 
with the endosomolytic active peptide-siRNA hybrid described in chapter 3.1. If the 
endosomal escape is the only remaining bottleneck of the system, this combination 
should lead to an efficient knockdown in KB cells, stably expression eGFP-Luciferase. 
To show the necessity and functionality of all substructures not only in special 
designed experimental settings but also during in vitro transfection, controls lacking 
targeting, crosslinking ability, the endosomolytic peptide or the reducible linkage 
between Inf7 and siRNA were used for transfection as well (Fig. 3.32). 
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Fig. 3.32 In vitro gene silencing combining FolA-PEG24-K(Stp4-C)2 with Inf7-siRNA. Folic acid 
receptor positive KB cells stably expressing the eGFP-Luciferase gene were transfected with FolA-
PEG24-K(Stp4-C)2 combined with Inf7-siGFP (I), FolA-PEG24-K(Stp4-C)2 combined with Inf7-Mal-siGFP 
(II), FolA-PEG24-K(Stp4-C)2 combined with siGFP (III), A-PEG24-K(Stp4-C)2 combined with Inf7-siGFP 
(IV), FolA-PEG24-K(Stp4-S)2 combined with Inf7-siGFP (V) or FolA-PEG24-K(Stp4-C)2 combined with 
Inf7-siCtrl (VI). 3-20: used nitrogen to phosphate (N/P) ratio for polyplex formation.  
 
As expected, the only combination of structures that leads to a specific knockdown, is 
the functional carrier in combination with the endosomolytic active siRNA. All other 
structures do not show any effect on gene expression. The only controls showing a 
slight concentration dependent knockdown, is the combination of the functional carrier 
with unmodified siRNA or same construct with non-reducible linkage between Inf7 and 
siGFP, indicating that the endosomal escape has been a crucial bottleneck. 
        I                    II                  III                   IV                 V                   VI 
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After the specific knockdown of an “artificial” gene could be demonstrated, this system 
was used to silence the endogenous target EG5 (KSP). This protein is active in 
spindle formation during mitosis. Literature describes that the down regulation of this 
protein leads to a mitotic arrest, showing a characteristic mitotic figure in the nucleus 
(aster formation).141 As this allows readout by microscopy, this system was chosen as 
endogenic target. The comparison of the targeted carrier with the untargeted analogue 
led to the results shown in Fig. 3.33. 
 
 
Fig. 3.33 Microscopic pictures of in vitro knockdown experiments using EG5 as endogenic 
target. KB cells were transfected using Inf7-siEG5 in combination with FolA-PEG24-K(Stp4-C)2 (A) or A-
PEG24-K(Stp4-C)2 (C), or Inf7-siCtrl in combination with FolA-PEG24-K(Stp4-C)2 (B) or A-PEG24-K(Stp4-
C)2 (D). Arrows: detected spindle arrest. The experiment was performed by Daniel Edinger as part of 
his PhD thesis (in preparation). 
 
As the microscopic pictures demonstrate, the only experimental setting showing the 
specific mitotic figure is the combination of FolA-PEG24-K(Stp4-C)2 with Inf7-siEG5 for 
transfection (Fig. 3.33 A). In all other settings no aster formation could be observed 
(Fig 3.33 B-D). 
 
Summarizing this chapter, the synthesis of a pure and defined polycationic carrier 
including shielding and targeting could be demonstrated. The functionality of the 
substructures could be shown, resulting in an efficient and specific gene silencing in 
vitro. 
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3.3.5 Biodistribution of siRNA using FolA-PEG24-K(Stp4-C)2 in combination with 
Inf7-siRNA  
 
After the positive results of characterization and evaluation of the new carrier system 
in vitro, it was decided to test the efficiency of the delivery system in vivo. For this 
purpose KB cells were used in a subcutaneous tumor model in NMRI nude mice.  
As the particle size of the designed carrier system was measured to be around 6 nm 
in diameter and therefore below the molecular cut off of the kidney, it was hypothized 
that these particles are not able to circulate stable after systemic application. This 
could be demonstrated in initial experiments (data not shown). Therefore different 
analogues have been designed and synthesized in a further screen to increase the 
particle size and explore the particle behaviour during systemic circulation. Two 
concepts were chosen: 
 
- elongation of the PEG chain for an increased shielding layer 
- incorporation of lipid structures to force agglomeration to bigger particles 
and/or interactions with blood compounds  
 
These criteria led to the structures shown in Fig. 3.34 and 3.35 for the in vivo screen. 
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Fig. 3.34 FolA-PEG24-K(Stp4-C)2 analogues with increased PEG length. 
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Fig. 3.35 FolA-PEG24-K(Stp4-C)2 variations with hydrophobic modifications. 
 
The elongation of the PEG chain was performed, repeating the conjugation step of 
Fmoc-amido-dPEG24-acid two- or three times. As hydrophobic domains for increased 
aggregation and interaction with blood compounds three different variants were 
tested: tyrosines as short hydrophobic domain, caprylic acid with a medium length, 
and stearic acid as long hydrophobic modification.  
After synthesis these carriers were used in combination with Inf7-siRNA to determine 
the influence of the modification on the particle size of the polyplex. Therefore the 
diameter was determined by fluorescence correlation spectroscopy (FCS) 
measurements. Results (table 3.8) demonstrate that these small variations in carrier 
design lead to significant differences in particle size. 
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Table 3.8 Particle size of polyplexes of different carrier variants and Inf7-siRNA. Particles have 
been formed in HBS buffer. rh: hydrodynamic radius. 
 
 
The elongation of the PEG chain has a moderate effect, increasing the hydrodynamic 
radius from 3.0 nm (1 PEG) to 3.2 nm (2 PEG) and 4.4 nm (3 PEG). In contrast the 
hydrophobic modifications led to particles with great differences in particle size. While 
the tyrosine motif did not change the particle size, modification with caprylic- and steric 
acid resulted in particles with a size of 16.9 and 160 nm. 
To exclude that the modification of the structure leads to a negative impact on toxicity 
or silencing efficiency all structures were tested in the standard in vitro screen as 
explained under 3.3.4 (Fig. 3.36).  
 
Carrier rh [nm]
FolA-PEG48-K(Stp4-C)2 3.2 (± 0.1)
FolA-PEG72-K(Stp4-C)2 4.4 (± 0.1)
FolA-PEG24-K(Stp4-Y3-C)2 2.8 (± 0.2)
FolA-PEG24-K(Stp4-K(K(CapA)2-C)2 16.9 (± 0.2)
FolA-PEG24-K(Stp4-K(K(SteA)2-C)2 160.3 (± 0.6)
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Fig. 3.36 In vitro gene silencing, using different variations of FolA-PEG24-K(Stp4-C)2. Folic acid 
receptor positive KB cells stably expressing the eGFP-Luciferase gene were transfected with the 
different modified versions of FolA-PEG24-K(Stp4-C)2 in combination with siGFP (white bars) siCtrl (light 
grey bars), Inf7-siGFP (dark grey bars) or Inf7-siCtrl (black bars). 3-20 used nitrogen to phosphate (N/P 
ratio for polyplex formation. Data is presented as relative value compared to HBG treated cells. 
 
The transfection results show that the modification of the carrier backbone has a 
strong influence on the silencing efficiency in vitro. For the two constructs with the 
elongated PEG chain (FolA-PEG48-K(Stp4-C)2 and FolA-PEG72-K(Stp4-C)2) the 
combination with Inf7-siRNA resulted in a specific reporter gene silencing comparable 
with the efficiency of the initial construct (FolA-PEG24-K(Stp4-C)2), while transfection 
with unmodified siRNA resulted in absence of gene regulation. In contrast to this 
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finding the combination of the three hydrophobic modified versions of the model 
compound with Inf7-siRNA did not result in an efficient knockdown. The use of FolA-
PEG24-K(Stp4-Y3-C)2 showed a medium silencing effect of approximately 50% 
expression under used conditions, while the use of fatty acid modified carriers did not 
result in a significant difference in reporter gene silencing between Inf7-siGFP and 
Inf7-siCtrl or unconjugated siRNA. In contrast to the PEG variants carriers containing 
fatty acids led to a medium (in case of stearic acid) or high (in case of caprylic acid) 
concentration dependent toxicity. 
 
Although not all constructs were efficient in in vitro gene silencing, the constructs were 
used to perform studies on the influence of particle size on the biodistribution in vivo. 
For this purpose polyplexes of the single constructs in combination with 50 µg Cy7 
labeled siRNA in an N/P ratio of 16 were injected intravenously into NMRI nude mice, 
carrying a subcutaneous KB tumor. Animals were imaged 0.25, 1 and 4 h after 
injection by near infrared fluorescence imaging using an IVIS Lumina system. 
Exemplary images of one animal per group are shown in Fig. 3.37 and 3.38. 
 
Fig. 3.37 Biodistribution of siRNA in combination with different polycationic backbones, ventral 
position. Polyplexes containing Cy7-labeled siRNA and one of the six targeted, polycationic backbones 
were injected systemically into NRMI nude mice. Mice were imaged 0.25, 1, 4 h after injection. The 
experiment was performed by Laura Schreiner and Daniel Edinger as part of their PhD thesis (in 
preparation). 
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Fig. 3.38 Biodistribution of siRNA in combination with different polycationic backbones, dorsal 
position. Polyplexes containing Cy7-labeled siRNA and one of the six targeted, polycationic backbones 
were injected systemically into NRMI nude mice. Mice were imaged 0.25, 1 and 4 h after injection. The 
experiment was performed by Laura Schreiner and Daniel Edinger as part of their PhD thesis (in 
preparation). 
 
As demonstrated by the NIR fluorescence images the different structures of the 
polycationic carriers led to alterations in biodistribution. Comparing the carriers with 
altered PEG length no significant changes can be observed. All particles do not 
interact with any tissue and are cleared efficiently via renal filtration. In contrast 
particles with hydrophobic modifications showed a different behaviour. With increasing 
hydrophobicity (Y3<CapA) the particles have an increased delay within the liver before 
the Cy7 signal appears in kidney and bladder. Particles containing stearic acid 
showed a strong accumulation in the lung and a high toxicity. The animal died after 
injection. 
 
As the detected Cy7 label was covalently attached to the backbone of the siRNA the 
imaging experiments show just the distribution of siRNA molecules and not of siRNA 
bound in a polyplex. Thus the fast renal filtration could be a result of a low particle 
stability and thus filtration of released siRNA and not of particles. In case of 
hydrophobic modified particles, this could be excluded due to the observed retention 
in liver or lung that cannot be observed in case of the injection of free siRNA. To prove 
the theory of stable particles that are cleared due to small size, the urine of mice was 
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checked for appearance of particles and free siRNA after systemic administration of 
FolA-PEG24-K(Stp4-C)2 and FolA-PEG72-K(Stp4-C)2. For this purpose the urine was 
analyzed in an agarose gel with (+) or without (-) preincubation with particle disruptive 
agents (Fig. 3.39). 
 
Fig. 3.39 Gel migration assay of urine samples. Urine of NMRI nude mice was collected by 
punctuation 4 h after systemic injection of polyplexes containing Inf7-siRNA in combination with FolA-
PEG24-K(Stp4-C)2, (1PEG) or FolA-PEG72-K(Stp4-C)2, (3PEG). C: Control (free siRNA as internal 
standard; free siRNA: siRNA that has been injected without complexation with polymer. -: Sample was 
analyzed without further treatment, +: Sample was treated with TCEP and heparin and incubated for 
10 min before analysis. The experiment was performed by Laura Schreiner as part of her PhD thesis (in 
preparation). 
 
In this gel migration assay urine samples of animals treated with polyplexes of siRNA 
with the two polycations were compared with the urine of animals treated with free 
siRNA and a siRNA sample that has not been injected into an animal. Both control 
siRNA samples show a similar migration pattern. Thus free siRNA is rapidly cleared 
via the kidney and not processed inside the body. Although the migration distance is 
slightly different when the samples were preincubated with TCEP and heparin, the 
strength of the band is not altered. In comparison, the urine samples of mice treated 
with polyplexes show a different pattern. While there is just a minimal signal of free 
siRNA if the urine is not preincubated with TCEP and heparin, the band signal 
increases significantly when the polyplex destabilizing agents are used. This indicates 
that the signal detected in the urine by imaging experiments is labeled siRNA bound in 
polyplexes. Thus the polyplexes are stable during blood circulation and are cleared if 
not detected by the target tissue. 
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The absence of a Cy7 signal in the tumor tissue does not necessarily result in the 
absence of gene knockdown. Just few siRNA molecules might have to enter the tumor 
cells to result in efficient target gene silencing. Therefore Inf7-siEG5 was injected in 
combination with FolA-PEG24-K(Stp4-C)2 using the same in vivo model as already 
described. At 24 h after treatment animals were sacrificed, tumors harvested and 
analyzed for mitotic figure by cryosection and microscopy (Fig. 3.40). 
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Fig. 3.40 Aster formation after systemic application of Inf7-EG5. 24 h after systemic treatment of 
NMRI mice, bearing a subcutaneous KB tumor, with Inf7-EG5 in combination with FolA-PEG24-K(Stp4-
C)2 or controls, tumors were harvested. Slices were stained with DAPI to visualize the nucleic. Arrows: 
detected mitotic figures. The experiment was performed by Laura Schreiner and Daniel Edinger as part 
of their PhD thesis (in preparation). 
 
The tumor sections show aster formation when EG5-siRNA was injected either in 
combination with the targeted or the nontargeted polycation. Treatment with control 
siRNA did not result in the formation of mitotic figures. Thus gene silencing could be 
demonstrated, although just small amounts of siRNA enter the tumor tissue. As the 
detection of mitotic figures is just a semiquantitative method, a clear benefit of folic 
acid targeted particles could neither been proved nor been disproved. Therefore 
further experiments had to be carried out. 
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3.3.6 Proving in vivo tumor targeting via intratumoral treatment. 
 
In the last section the behaviour and functionality of the designed carrier system was 
evaluated in vivo. It could be demonstrated, that the particles are stable during blood 
circulation, inert to nontargeted tissue and cleared when not recognised by the target 
tissue. Although just small amounts of siRNA reached the tumor side, the carrier 
system was efficient enough to lead to target gene silencing as shown by the 
appearance of mitotic figures after treatment with Inf7-siEG5. Although more asters 
were observed for targeted structures, in the analyzed tumor slices, this method is not 
applicable for quantification. An in vivo bioimaging method should give a more 
quantitative result for the targeting ability of a carrier system. As the detection of the 
Cy7 signal after systemic administration was not sensitive enough to quantify the 
accumulation of siRNA in the tumor tissue, the amount of siRNA that reaches the 
tumor should be maximized in a second imaging experiment. Therefore labeled siRNA 
was injected intratumoral into the subcutaneous KB NMRI nude model. 
The tumor signal of free siRNA was compared to polyplexes in combination with either 
FolA-PEG24-K(Stp4-C)2 or A-PEG24-K(Stp4-C)2. Resulting kinetic is shown in Fig. 3.41. 
 
0 50 100 150
5.0×1008
1.0×1009
1.5×1009 FolA-PEG24-K(Stp4-C)2
A-PEG24-K(Stp4-C)2
free siRNA
time after injection [h]
to
ta
l f
lu
x
/a
re
a
 
Fig. 3.41 Tumor retention of folic acid targeted polyplexes. After local injection of 50 µg Cy7-
labeled siRNA in combination with FolA-PEG24-K(Stp4-C)2 or its controls in a N/P ratio of 16, animals 
were imaged for NIR fluorescence every 24 h. The experiment was performed by Laura Schreiner and 
Daniel Edinger as part of their PhD thesis (in preparation). 
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The intratumoral application of labeled siRNA shows a significant increased retention 
of targeted polyplexes over nontargeted polyplexes and free siRNA. These data prove 
that tumor targeting by folic acid results in polyplexes with an increased affinity to its 
target tissue. 
 
In conclusion this chapter demonstrates the synthesis of a molecular defined, 
monodisperse, polycationic carrier by solid phase supported peptide synthesis. This 
carrier bears special functionalities, addressing single steps during the delivery 
process. Due to the synthesis strategy, the design of the molecule can be controlled in 
every single detail. In combination with Inf7-siRNA this carrier is able to silence a 
specific gene in vitro, demonstrating the synergistic effect of the single functional 
domains. Although resulting particles were shown to be very small and thus get 
cleared via the kidney, these particles were able to generate gene silencing in their 
target tissue and show high tolerability to the animal, due to a perfect shielding. 
Significant influence of the targeting moiety was demonstrated by intratumoral 
application of this complex carrier. 
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4 Discussion 
 
4.1 An endosomolytic active peptide-siRNA hybrid as structural defined 
molecule for enhanced endosomal escape in siRNA carrier systems 
 
The delivery of siRNA to target cells is a very complex process, wherein many 
different steps play a role. A perfect delivery system addresses every single step of 
this process, overcoming its limitation as efficient as possible. One of the most crucial 
hurdles is the escape out of the endosomal compartment. After cell attachment of the 
delivery system via unspecific ionic interactions or via specific target cell interactions, 
common polyplexes are taken up into the cell by endocytosis. The resulting 
endosomes are further processed to lysosomes in order to inactivate their payload 
and protect the cell. Thus an efficient escape out of the endosome is crucial for a 
functional carrier system. Overcoming this hurdle, different approaches have been 
investigated that can be divided into two groups. One possibility is the enhancement of 
the buffering capacity of the carrier system, based on e.g. ethylenimine units145 or the 
incorporation of histidines.146 The second possibility is the incorporation of membrane 
active structures like fatty acids or lytic peptides.128, 147 Both approaches imply the 
chemical modification of the carrier system. Working with polymers and common linker 
chemistry, this leads to very heterogenic products. In general the chemical 
characterization is limited or disabled. 
For the current study structural definition of compounds was a key criterion. Thus the 
idea was to design an endosomolytic active peptide-siRNA hybrid. This structure 
should be combined with a polymeric delivery system (with or without endosomal 
escape ability) to improve its efficiency. A peptidic endosomolytic modification in 
contrast to a polymeric buffering domain was chosen, because published work already 
showed that the incorporation of such peptides into a carrier system leads to a 
strongly enhanced delivery.123, 128 The attachment of the peptide to siRNA was chosen 
for different reasons. (i) The hybrid leads to a covalent attachment of endosomolytic 
domain and siRNA and therefore to a stable interaction of structures that have to end 
up in one endosome to be functional. (ii) This design leads to a structural defined 
molecule. To show a general proof of concept, Inf7, a designed peptide based on the 
amino-terminus of the influenza virus hemagglutinin was chosen as model peptide. Its 
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negatively charged sequence minimises undesired interactions with the siRNA, while 
its pH dependant lytic activity has shown to enhance the endosomal escape of 
delivery systems.123 
For the synthesis of the construct a thiol modified siRNA has been chosen. The 
conjugation was performed by activation of the thiol group followed by attachment of 
the cysteine modified peptide (Fig. 3.1). This synthesis route allows a controlled 
reaction. The siRNA is highly soluble under aqueous conditions. Its high charge 
density allows a fast and scalable purification. Thus educts such as DTNB and Inf7 
can be used in high excess, shifting the reaction to the product side. Furthermore this 
reaction type enables an easy adoption to other siRNA sequences and different 
peptides. As shown in chapter 3.2 the same protocol has shown to be effective for the 
synthesis of targeted and pegylated siRNA constructs. Qualitative (Fig. 3.4) as well as 
quantitative analyses (Fig. 3.3) revealed the identity of the reaction product and a 
purity above 95%. 
The covalent conjugation of peptides to siRNA has already been published by different 
groups. Leading approaches show the covalent attachment of cell penetrating 
peptides (CPPs) or protein transduction domains (PTDs) to the siRNA backbone.148-151 
These peptides are derived from sequences of proteins that are able to cross the cell 
membrane. The conjugation was performed to mediate cellular uptake of siRNA by 
cells. In all these approaches the conjugation was performed in different ways. Acid 
cleavable linkers have been used as well as linkers cleaved under reductive 
conditions or non-cleavable linkers. But literature reveals that the possibility of siRNA 
modification is discussed controversial.142 Modifications have been described at all 
four ends of the siRNA double strand.150-153 A modification of siRNA always can have 
an influence on its silencing efficiency. To be active, the siRNA has to be recognized 
by, and incorporated into the RISC. A modification of one end could alter its structural 
accessibility and thus hamper the interaction with the RISC, resulting in a reduced 
activity. The position of the attachment as well as the type of linkage has therefore to 
be chosen carefully. In most cases a reduced activity has been explained by delivery 
processes, but a side by side comparison of the activity of modified and unmodified 
siRNA has just been performed in a few cases.151, 154 In this approach the 
endosomolytic active peptide Inf7 was covalently attached to the 5’-end of the siRNAs 
sense strand. As it is reported that the 5’-end of the antisense strand is very important 
for RNA interference, this position should be the least influencing position and thus 
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ideal for conjugation. The functionality assay revealed that our hypothesis was right. 
The modification of the antisense strand with Inf7 at this position did not influence its 
activity (Fig. 3.6). 
A second important question in the design of a peptide-siRNA hybrid is the influence 
of the siRNA attachment on the activity of the peptide. In case of CPPs or PTDs no 
separate examination has been described yet. In this thesis the lytic activity of the 
attached peptide could be demonstrated in an isolated assay (Fig. 3.5). Incubation of 
erythrocytes with free Inf7 peptide and the Inf7-siRNA hybrid revealed that the 
covalent modification with a negatively charged macromolecular siRNA does not 
influence the peptides activity nor its pH specificity in this conjugate. Within these 
experiments it could be shown in a side by side comparison in isolated assays that the 
activity of both, siRNA and Inf7 peptide are not significantly influenced by the 
synthesis of a hybrid structure.  
Further experiments combining endosomolytic siRNA and polymers with a low 
endosomal escape efficiency (Fig. 3.8 and Fig. 3.32) show that this construct is able to 
increase the silencing efficiency of the carrier system. Control experiments reveal that 
the raised activity is due to an enhancement of endosomal escape. Both tested 
polymers, the nontargeted structure 76, as well as the targeted polymer 
FolA-PEG24-K(Stp4-C)2 do just show an increased knockdown if peptide modified 
target siRNA is used. All controls lacking either the peptide or the siRNA target 
sequence do not lead to an efficient down regulation of expression. As an increased 
particle size (e.g. due to aggregation) is known to have an influence on the silencing 
efficiency in vitro, it was checked, if the modification leads to an altered polyplex 
formation. Results showed that particles formed with modified siRNA do not differ from 
particles formed with unmodified siRNA (Fig. 3.7, table 3.2). 
In combination with FolA-PEG24-K(Stp4-C)2 it could also be shown that the disulfide 
bridge connecting siRNA and peptide is very important. A control, where the reducible 
disulfide bond is replaced by a non-cleavable maleimid, resulted in a strong reduction 
of gene knockdown. Thus it seems to be very important for the silencing efficiency of 
the siRNA that the peptide is cleaved in the reductive cytosolic environment to result in 
an active siRNA (Fig. 3.32).  
Concluding these results, the synthesis of a structural defined hybrid of functional 
siRNA and endosomolytic active Inf7 peptide could be realized. Structure and purity 
could be verified. The functionality of the substructures has been shown in detail 
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leading to an efficient delivery system when combined with a polycationic carrier. 
Raised activity in comparison to unmodified siRNA could be shown to be exclusively 
due to an enhanced endosomal escape. Thus endosomolytic siRNA displays a 
beneficial method to overcome the bottleneck of endosomal escape. This increases 
the design space of used carriers, because they are no longer limited to an own 
endosomal escape ability.    
 
 
4.2 Targeted siRNA as defined structure for enhanced cell specifity and uptake 
 
RNA interference takes place in the cytosol. Thus siRNA has to cross the cellular 
membrane to become an active drug. As negatively charged macromolecule, the 
nucleic acid needs a delivery system to overcome this hurdle. Besides endosomal 
escape (discussed in section 4.1) the specific attachment and uptake by the cell is one 
of the main limitations during the delivery process. Basic approaches on siRNA 
delivery with polymers used the positive charge of the resulting polyplex to attach to 
the negative charged cell surface. This rather unspecific attachment leads to cell entry 
via endocytosis.145 This method has been shown to result in gene silencing under in 
vitro as well as under in vivo conditions for several polymers. Although the method is 
very efficient, it bears disadvantages. Positive charged polyplexes have the same 
affinity to all cells, not distinguishing between target and nontarget cells. This causes 
undesired transfection of cells and thus side effects especially in vivo. For an efficient 
delivery the polyplex has to be highly charged which also leads to interactions with 
several compounds in the extracellular environment, resulting in aggregation or loss of 
function. To reduce side effects and increase siRNA delivery to target cells, specific 
ligands have been incorporated into the delivery vehicle. These ligands address 
specific receptors, ideally highly expressed on target cells. Attachment of the ligand to 
the receptor results in specific internalization of the carrier.  
Incorporation of specific ligands into a carrier system has been described using 
several methods. The type of conjugation can be separated into two main groups. 
Either the ligand is attached covalently to the polymer105, 155 or to the siRNA 
backbone.156-157 
As described in chapter 3.2 a targeted siRNA was synthesized enabling the specific 
delivery of the nucleic acid to its target cell in this work. As structural definition was the 
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main topic of this thesis a synthesis route had to be designed that allowed the 
construction of a molecular defined ligand structure and a conjugation method that 
allows the purification and identification of the product. 
As synthesis platform for the ligand structure, Fmoc based solid phase supported 
peptide synthesis (SPPS) was chosen. This method first published by 
Merrifield et al.137 allows the controlled generation of defined macromolecules on a 
solid support using a high excess of educts, eliminating unreacted material by simple 
filtration steps. Although this strategy allows the generation of pure products it limited 
the choice of ligands to structures that can be integrated via a solid phase coupling 
step. Besides peptide ligands like GE11 or B6, folic acid displays a feasible structure 
for SPPS. Being composed of glutamic acid and pteroic acid connected via an amide 
bond, this structure could be synthesized in two steps on solid support, as already 
been shown by Kazanova et al..118 Protected educts were commercially available and 
therefore an ideal candidate for targeting. Folic acid was preferred as model, because 
it is a small molecular ligand with a high binding affinity to its receptor. It has been 
used in several approaches for targeted delivery to tumor cells. Its ligand is reported to 
be upregulated in many different cancer types,111-112 while it is almost absent on other 
cells, despite of the apical membrane of epithelial cells in the kidney proximal 
tubules115 and activated monocytes and macrophages.116 Therefore it bears all criteria 
for an efficient model structure. In general targeting ligands, especially small 
molecules are attached to its cargo via a polyethylene glycol (PEG) spacer. This 
structure allows the local separation of targeting moiety from the nucleic acid and thus 
an increased recognition by the receptor. Considering structural definition, the PEG 
spacer in general represents the most crucial part in these kinds of constructs. In 
similar constructs described in literature, bifunctional PEG linkers have been used.158-
160
 The ligand has selectively been attached to one side, the siRNA to the other side. 
The application of two different reaction types for attachment limits the use of ligand 
structures and decreases precision. As these PEG-linkers are synthesized by random 
polymerization, they show a high degree of polydispersity. In the approach described 
in this thesis, a monodisperse PEG chain was used bearing exactly 24 ethylene glycol 
subunits (dPEG24). As this structure is commercially available with a ω-carboxyl and 
an Fmoc-protected α-amino group, it can easily be introduced into the targeting 
structure via SPPS. As coupling domain for the attachment of the siRNA two different 
structures have been evaluated. First the synthesis was performed similar to the 
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construction of the endosomolytic siRNA using a terminal cysteine for disulfide 
formation (Fig. 3.12). Improving the synthesis, the ability to use the 1,3-dipolar 
cycloaddition was explored. Thus cysteine was replaced by an azide containing 
building block in later syntheses (Fig. 3.17). For the first studies, the attachment was 
performed as already described for the peptide-siRNA hybrid via a disulfide bond. This 
bond was used for two reasons. (i) It allowed performing the synthesis analogous to 
the synthesis of Inf7-siRNA. (ii) Disulfide bonds are thought to be cleaved under the 
reductive cytosolic environment. Incorporation of a disulfide bond allows the removal 
of the ligand-PEG structure after cell entry and thus avoids undesired effects. As 
shown in Fig. 3.14 this strategy leads to a pure and functional conjugate after 
purification. The disadvantage of this synthesis is its laborious, material- and time-
consuming strategy. Three reaction steps (deprotection, activation and coupling) have 
to be performed, each intermitted by a purification step. As the purification always 
leads to a loss of 10-20% of the material, shorting the synthesis route would be 
beneficial. The 1,3-dipolar cycloaddition displays a reaction type that is reported to be 
very efficient and does not lead to undesired side reactions. Thus it was a useful tool 
to generate ligand attached siRNA. As mentioned before, the synthesis of the SPPS 
generated part of the construct was adapted for this purpose by exchanging the thiol 
bearing cysteine against (S)-5-Azido-2-(Fmoc-amino)pentanoic acid. The siRNA was 
modified by an alkyne linker, allowing the coupling of the altered construct. The 
disulfide remained in the structure and was included in the alkyne linker (see 
Fig. 3.17). This strategy allowed the conjugation via a one-step synthesis and one 
purification step. The resulting product showed same purity and functionality as the 
former construct. Thus the 1,3-dipolar cycloaddition displays an efficient reaction 
method for the construction of precise structures. 
Functionality assays for the determination of the effect of the conjugation on the 
biological activity of ligand as well as of siRNA were performed. Using a polymer that 
already had been reported to work efficiently for siRNA delivery in vitro showed that 
neither the conjugation of PEG nor the additional modification with folic acid influences 
the silencing efficacy of the siRNA (Fig. 3.21). This result is consistent with the results 
obtained with Inf7-siRNA. The modification of the double stranded nucleic acid at the 
5’-end of its sense strand does not influence the siRNA activity, when the attachment 
is performed via a reducible disulfide bond. In a second assay the binding ability of 
folic acid to its receptor was determined after coupling. The conjugation of folic acid to 
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a polymer or biomolecule for cell specific targeting has already been reporter in 
different publications. The most discussed point is the influence of conjugation on the 
activity of the ligand. The attachment can be performed via one of the two carboxyl-
groups. As it has been shown, that the attachment via the α-carboxyl group results in 
a strong reduction in receptor affinity, the optimal position would be the γ-carboxyl 
group of the glutamic acid. In common solution chemistry the conjugation is in general 
performed by activation of the carboxyl group and conjugation to an amino function. 
As this method does not allow a determination between the α- and γ-carboxyl function, 
this leads by theory to ~50% product carrying a ligand with reduced activity. Within the 
synthesis and conjugation method presented in this thesis, the attachment of PEG-
spacer and siRNA was always performed to 100% at the γ-carboxyl function. 
Therefore all of the modified molecules should retain its high affinity to the receptor. 
This could also be underlined by uptake studies of the free FolA-PEG24-click-siRNA 
conjugate. The flow cytometric analysis (Fig. 3.20) as well as the fluorescence 
microscopy (Fig. 3.19), using labeled siRNA, shows an efficient and very specific 
uptake of the conjugate via the folic acid receptor. 
Although it has been proven in single assays that both biomolecules retain its 
functionality after conjugation, it does not lead to gene silencing after transfection of 
folic acid receptor expressing KB cells. The same findings were already observed in 
the work of Thomas et al.,157 where they also did not find any functionality of a similar 
but more imprecise targeted structure. The reason for the negative result could be 
shown during this thesis. As no functionality for endosomal escape was incorporated 
into the structure, the transfection route could not be completed and therefore did not 
result in gene silencing. This hypothesis could further be underlined, combining the 
defined structure with a defined polycation, having an endosome disruptive proton 
sponge property in one polyplex. Addressing this last step of in vitro delivery, the 
construct mediated a very efficient knockdown of the target gene (Fig. 3.24). 
In summary, chapter 3.2 proves that the synthesis of a defined monodisperse 
conjugate of folic acid, PEG and siRNA can be realized. The presented design and 
strategy allows the control of the molecular structure of the conjugate and enables a 
clear and distinct analysis with state-of-the-art methods. Due to the knowledge of 
published findings on the influence of attachment site on activity, the synthesis 
resulted in a macromolecule with maximal activity. Although this structure is not able 
to address every single step during the delivery process, it results in specific and 
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efficient gene silencing when combined with an endosomolytic active polycation. Thus 
the molecule reduces the role of the polycation to polyplex formation and endosomal 
escape and therefore increases its design space.  
 
 
4.3 The combination of a structurally defined, targeted polymer and an 
endosomolytic active peptide-siRNA hybrid results in a delivery system for 
specific gene silencing in vitro as well as in vivo 
 
As already described in the last section, targeting is a crucial step in the delivery of 
nanoparticles. Besides covalent attachment of a targeting ligand to the backbone of 
siRNA described in chapter 3.2, coupling the ligand to the polycationic backbone is the 
most popular strategy in the design of targeted polyplexes. Methods described in 
literature, in general use polymers with a high polydispersity and chemistry based on 
rather random attachment of linker molecules to the polymeric side chains.57 This 
strategy leads to the desired result of a targeted polyplex but bears several problems. 
(i) The high polydispersity of the polymer in combination with the imprecise chemistry 
results in a very heterogenic mixture of molecules. Further incorporation of e.g. 
endosomolytic or shielding domains would further increase the heterogeneity. (ii) The 
resulting polymers fail any possibility of precise structural analysis. The only 
information that can be gained is an averaged ratio of molecules in the mixture. (iii) 
Data obtained from physical or biological evaluation of resulting polyplexes are just an 
average of influences of all single slightly differing molecules, making the analysis of a 
real structure activity relationship impossible. 
In this thesis part the design and synthesis of a polycationic backbone is described. 
Within this structure, a defined pegylation was incorporated for shielding purpose, 
combined with folic acid as targeting ligand. Goal of this construct was the design of a 
structural defined targeted polycationic macromolecule that allows clear functional 
evaluation of substructures. As model structure a polycationic backbone consisting of 
8 Stp units was chosen. Schaffert et al. already showed that this kind of short 
structures are not able to bind nucleic acids efficiently.140 Thus cysteines were 
incorporated at both ends of the chains to mediate crosslinking between the 
backbones after complexation. Functional assays on the nucleic acid binding ability 
(Fig. 3.29) indicate that this crosslinking is essential for the formation of stable 
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polyplexes. Hence transfection efficiency was absent, when the cysteines were 
replaced by serines (Fig. 3.32). These findings are consistent with literature, where 
short polycations have to be complexed before or after polyplex formation to generate 
stable carriers.75 The advantage of disulfide bridges is their biodegradability. After 
cellular transport of its payload the stabilized particles degrade into their small 
substructures due to cleavage of disulfide bonds in the reductive cytosolic 
environment. 
The carrier design included a pegylation to shield the polyplexes positive charge and 
generate a particle with low interactions with blood components and nontargeted cells. 
Thus a branching point was introduced into the backbone during synthesis by 
attachment of lysine. This branching point was used to attach a defined PEG chain 
consisting of exactly 24 ethylene glycol subunits. As this commercially available PEG 
was modified with a ω-carboxyl group and an Fmoc protected α-amino group, it was 
fully compatible to solid phase synthesis. This shielded polymer was tested for its 
functionality using different methods. Fluorescence correlation spectroscopy (FCS) 
measurements revealed that the shielded particles had a hydrodynamic radius of 
~3 nm (naked siRNA ~2 nm; table 3.5), while its zeta potential was around 0 mV (10-
14 mV lower than the control structure; table 3.7). This indicates that this structure is 
able to efficiently build small, fully shielded particles. Further experiments on cell 
association and transfection efficiency demonstrated that these fully protected 
particles do not interact with the cell surface and thus do not deliver siRNA in an 
unspecific manner (Fig. 3.30, 3.31, 3.32). The reduced interaction with the cell surface 
avoids undesired cell and protein interactions in vivo but necessitates the 
incorporation of a homing structure for the target cells. Folic acid presents a high 
affinity ligand which is also well compatible with solid phase supported synthesis. The 
incorporation of folate clearly showed that the lost transfection efficiency of a 
pegylated particle could be recovered (Fig. 3.28, Fig. 3.32). In flow cytometric 
analyses the targeted carrier showed a strongly enhanced uptake efficiency on 
receptor expressing cells and an almost absent cell association in nontargeted cells 
(Fig. 3.31). Several transfection systems have been designed in the last few years 
using folic acid as targeting domain. Although the attachment never was defined, 
leading to a loss of targeting efficiency, all these systems gave similar results on the 
strong targeting effect of this molecule.161 Despite the shown targeting, published data 
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up to now did not show a fully protected particle with absence of transfection efficiency 
without the ligand. 
Although the biophysical behaviour of the particles was as expected, they did not 
show any transfection efficiency due to a lack of endosomal escape (Fig. 3.28, 
Fig. 3.32). It was hypothesized that the Stp units lead to disruption of the endosomal 
compartment, forcing the proton sponge effect. Transfection results with DNA and with 
siRNA show that this effect is not strong enough. This finding could be explained by 
the phenomenon, known as “PEG dilemma”.162 It is reported that the endosomal 
escape ability of functional polymers gets strongly reduced by the incorporation of 
PEG into its structure. As the PEG per polycation ratio is very high in the designed 
carrier, this could explain its behaviour after internalization. To enhance the delivery 
process the structural defined polycationic carrier was combined with the 
endosomolytic peptide-siRNA hybrid in one carrier system. This combination resulted 
in a very defined efficient delivery vehicle addressing every limitation during the 
delivery process. Moreover efficient silencing of an “artificial” as well as an 
endogenous target could be achieved in vitro. 
In vivo delivery studies could further demonstrate the specific characteristics of the 
carrier system. As already performed during in vitro characterisation, the particle 
properties were checked step by step using different assays and readout systems. 
Flow cytometry and fluorescence microscopy could also prove in cell culture that 
unspecific interactions with nontargeted cells could be strongly reduced due to charge 
neutralization by pegylation. In vivo results on biodistribution confirm these results. In 
contrast to published work, showing almost always accumulation in liver and spleen 
(due to clearance by the reticuloendothelial system) or lung (due to aggregation and 
ionic interactions) these particles circulate stably without interactions with any tissue or 
short time after systemic injection, but are rapidly cleared by the kidney (Fig. 3.37, 
Fig. 3.38). The only arising signal showing accumulation of siRNA can be detected in 
kidney and bladder. Consistent with the small particle size of 6 nm in diameter, these 
particles are efficiently cleared by kidney filtration. Analysis of urine fractions proved 
that the detected signal is not free uncomplexed siRNA after dissociation from 
unstable polyplexes, but the signal of siRNA bound in stable polyplexes (Fig. 3.39). As 
no tumor accumulation was found during these imaging experiments, it was 
hypothized that the circulation time is not long enough for the particle to “recognize” its 
target tissue. Hence the particle size was modified by redesigning the carrier and 
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modification of the backbone (Fig. 3.34, Fig. 3.35). The elongation of the PEG-chain 
by a factor of two or three resulted in an increase of particle size by a factor of only 1.1 
or 1.5. The incorporation of hydrophobic domains showed different results. Short 
hydrophobic modifications (Y3) did not alter the particle size, while longer hydrophobic 
chains (caprylic acid, stearic acid) resulted in bigger particles, having a diameter of 
33.8 nm or 320.4 nm. These results indicate that two factors influence the particle 
size. A high degree of pegylation leads to decreased particle size due to the 
generation of polyplexes with a low amount of siRNAs and reduced aggregation, while 
hydrophobic domains force aggregation, resulting in increased particle size. Studies 
on biodistribution prove this hypothesis (Fig. 3.37, Fig. 3.38). Small, pegylated 
polyplexes still circulate without unspecific interactions but show no significant 
enhanced circulation time triggered by the only slightly increased particle size. In 
contrast hydrophobic modifications show accumulation in liver or in case of stearic 
acid aggregation and accumulation in the lung. Thus these modifications did not result 
in the desired elongated circulation time due to strong side effects.  
Although no fluorescence signal could be detected during biodistribution studies, the 
system is efficient enough to result in gene regulation. Studies performed with Inf7-
siEG5 and FolA-PEG24-K(Stp4-C)2 showed specific mitotic figure formation after 
intravenous injection (fig. 3.40). As just small amounts of siRNA are necessary for 
these findings, this indicates that the delivery route can be completed very efficiently. 
The low tumor signal after systemic injection as well as the semiquantitative readout of 
mitotic figure formation disabled a clear determination of the influence of the targeting 
ligand. The function of the targeting ligand is the attachment to its receptor and thus 
elongation of the retention, after the carrier reached the target tissue, and an 
increased uptake by the target cell. To prove the elongated retention time, the amount 
polyplexes reaching the tumor side was maximized by intratumoral injection. 
Measuring the fluorescence signal of injected polyplexes (Cy7 labeled siRNA 
complexed with FolA-PEG24-K(Stp4-C)2) showed a significant elongated retention in 
the tissue compared to nontargeted polyplexes and free siRNA (Fig. 3.42).
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5 Summary 
 
siRNA induced RNA interference is one of the most promising mechanisms for the 
treatment of various diseases including cancer. The introduction of siRNA into cells 
has been shown to allow the regulation of former undrugable targets. The most crucial 
limitation, hampering the development of a therapeutic drug, remains the delivery 
process. As many efforts had been invested in the improvement of polycationic 
delivery vehicles, as much the complexity of structures had increased. Carrier systems 
were modified with functional substructures that improve the different delivery steps by 
random attachment. This design results in very heterogeneous structures, preventing 
clear structure activity correlation studies. In this thesis multifunctional siRNA carrier 
systems were developed, composed of precise and well defined structures, allowing 
reproducibility, state-of-the-art analytics and the determination of a clear structure 
activity relationship. In one concept, siRNA was covalently attached to the pegylated 
targeting ligand folic acid. The structure was synthesized by solid phase peptide 
synthesis, using a PEG with a defined length. Via 1,3-dipolar cycloaddition or disulfide 
formation this structure was covalently attached to the siRNA backbone. This design 
allowed full control of the synthesis by purification and analysis. In in vitro assays it 
could be proven that this structure is able to get the siRNA efficiently across the 
cellular membrane via receptor mediated endocytosis but lacks the ability to escape 
the endosome. In combination with a defined polycationic carrier, enabling an efficient 
endosomal escape via the proton sponge effect, this carrier system enabled efficient 
receptor specific gene silencing. 
In a second approach, a polycationic carrier, composed of a cationic backbone, 
cysteines for nanoparticle stability by internal crosslinking, a defined PEG chain for 
shielding, and folic acid as targeting ligand was synthesized using solid phase 
supported peptide synthesis. Again a very defined monodisperse structure could be 
generated. Functionality of the structure regarding nucleic acid binding, crosslinking, 
shielding and receptor specific cell targeting could be demonstrated in separate 
assays in vitro. In combination with the third developed structure, an endosomolytic 
peptide- siRNA conjugate, this structure was able to overcome all single limitations 
during the delivery process resulting in very efficient and specific gene silencing in 
vitro. The nanosized appearance (only 6 nm hydrodynamic diameter) and complete 
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surface shielding of the particles was found very favourable for in vivo application 
tested in mice, resulting in a low accumulation in nontargeted tissue, clearance via the 
kidney and thus high tolerability by the organism after systemic application. 
Intratumoral injection proved increased tumor retention due to folic acid receptor 
targeting. Both intratumoral and intravenous injection resulted in specific target gene 
silencing in the folate-receptor expressing tumor. 
In conclusion, this thesis demonstrates that the synthesis of defined highly 
functionalized carrier systems is possible, allows the control of the appearance of the 
structures as well as its analysis via state-of-the-art methods. This design enables a 
full control over the carrier enabling the determination of a clear structure activity 
relationship. This thesis gives the proof of concept for the design of such carrier 
systems. Based on this strategy a tremendous variety of structures might be 
synthesized, providing numerous opportunities for the design of siRNA drugs.
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7 Appendix 
7.1 Abbreviations 
AA 
a.u. 
B6 
brPEI 
CapA 
CPP 
CTC-resin 
CuBr 
DAPI 
DCM 
DHB 
DIPEA 
DMF 
DMMAn 
DNA 
dsRNA 
DTNB 
EDTA 
e.g. 
EG5 
eGFP 
EGF-R 
EPR 
EtOH 
FCS 
Fe3+ 
Fig. 
Fmoc 
FolA 
FolA-R 
GALA 
Amino acid 
Absorption units 
Peptide sequence with affinity for the transferrin receptor 
Branched polyethylenimine 
Caprylic acid 
Cell penetrating peptide 
2-chlorotrityl chloride resin 
Copper bromide 
4',6-diamidino-2-phenylindole 
Dichloromethane 
2,5-dihydroxybenzoic acid 
Diisopropylethylamine 
N,N-Dimethylformamide 
2,3-Dimethylmaleic anhydride 
Deoxyribonucleic acid 
Double stranded ribonucleic acid 
5,5'-dithiobis-(2-nitrobenzoic acid) 
Ethylenediaminetetraacetic acid 
exempli gratia (for example) 
Eglin 5, or KSP, Kinesin spindle protein 
Enhanced green fluorescent protein 
Epidermal growth factor receptor 
Enhanced permeability and retention effect 
Ethanol 
Fluorescence correlation spectroscopy or Fetal calf serum 
Trivalent iron 
Figure 
Fluorenylmethyloxycarbonyl chloride 
Folic acid 
Folic acid receptor 
Peptide with the sequence Glutamic acid-Alanine-Leucine-Alanine 
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GE11 
GMP 
HEPES 
HES 
HBG 
HBS 
HOBt 
HPA 
KALA 
KCN 
Kd 
KSP 
LinA 
LPEI 
MALDI-TOF-MS 
 
MeOH 
MTBE 
mRNA 
n.d. 
N/P 
nt 
OEI 
OleA 
PAMAM 
pDNA 
PEG 
PEG24 
pHPMA 
PLL 
PPI 
PTD 
PyBop® 
Peptide binding to the EGF-receptor 
Good manufacturing practice 
N-(2-hydroxyethyl) piperazine-N’-(2-ethansulfonic acid) 
Hydroxy ethyl starch 
Hepes buffered glucose 
Hepes buffered saline 
Hydroxybenzotriazole 
3-Hydroxypicolinic acid 
Peptide with the sequence Lysine-Alanine-Leucine-Alanine 
Potassium cyanide 
Dissociation constant 
Kinesin spindle protein 
Linoleic acid 
Linear polyethylenimine 
Matrix-Assisted-Laser-Desorption/Ionization-Time-Of-Flight-Mass-
Spectrometry 
Methanol 
Methyl tertiary butyl ether 
Messenger ribonucleic acid 
Not defined 
Polymer nitrogen to nucleic acid phosphate ratio 
Nucleotide 
Oligoethylenimine 
Oleic acid 
Polyamidoamine 
Plasmid deoxyribonucleic acid 
Polyethylene glycol 
Polyethylene glycol with exactly 24 monomers 
poly(N-(2-hydroxypropyl)methacrylamide 
poly-L-lysine 
polypropylenimine 
protein transduction domain 
benzotriazole-1-yl-oxy-tris-(dimethylamino)- phosphonium 
hexafluorophosphate 
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rh 
RGD 
RISC 
RNA 
rpm 
RNAi 
RP-HPLC 
RT 
shRNA 
siRNA 
SPPS 
Stp 
TBE-buffer 
TBTA 
TCEP 
Tfa 
Tf-R 
TIS 
Trt 
v/v 
v/v/v 
w/v 
 
hydrodynamic radius 
peptide sequence (arginine, glycine, aspartic acid) 
ribonucleic acid induced silencing complex 
Ribonucleic acid 
Rounds per minute 
Ribonucleic acid interference 
Reverse phase high pressure liquid chromatography 
Room temperature 
Small hairpin ribonucleic acid 
Small interfering ribonucleic acid 
Solid phase peptide synthesis 
Succinoyl-tetraethylenpentamine 
Tris-Boric acid-EDTA-buffer 
Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine 
tris(2-carboxyethyl)phosphine 
Trifluoroacetic acid 
Transferrin receptor 
triisopropyl-silane 
trityl 
volume per volume 
volume per volume per volume 
weight per volume 
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7.2 Supporting Info Chapter 3.3 
 
Fig. 7.1 1H-NMR spectra of FolA-PEG24-K(Stp4-C)2 and A-PEG24-K(Stp4-C)2 in D2O. 
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Fig. 7.2 Analysis of structural analogues ofFolA-PEG24-K(Stp4-C)2. MALDI-TOF-MS spectra and 
chromatogram of the analytical RP-HPLC of FolA-PEG24-K(Stp4-S)2 (a,c) and A-PEG24-K(Stp4-C)2 (b,d). 
Calculated mass [M+H]+: FolA-PEG24-K(Stp4-S)2: 4043, A-PEG24-K(Stp4-C)2: 3720. 
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